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A B S T R A C T
Bacteriophage particles are the most abundant biological entities on our planet, infecting speciﬁc bacterial hosts
in every known environment and being major drivers of bacterial adaptive evolution. The study of bacteriophage
particles potentially sheds light on the development of new biotechnology products. Bacteriophage therapy,
although not new, makes use of strictly lytic phage particles as an alternative in the antimicrobial treatment of
resistant bacterial infections and is being rediscovered as a safe method due to the fact that these biological
entities devoid of any metabolic machinery do not have aﬃnity to eukaryotic cells. Furthermore, bacteriophage-
based vaccination is emerging as one of the most promising preventive strategies. This review paper discusses
the biological nature of bacteriophage particles, their mode(s) of action and potential exploitation in modern
biotechnology. Topics covered in detail include the potential of bacteriophage particles in human infections
(bacteriophage therapy), nanocages for gene delivery, food biopreservation and safety, biocontrol of plant pa-
thogens, phage display, bacterial biosensing devices, vaccines and vaccine carriers, bioﬁlm and bacterial growth
control, surface disinfection, corrosion control, together with structural and functional stabilization issues.
1. Introduction
Bacteriophages (or phages, viruses that infect bacteria) are the most
abundant entities on our planet, being harmless for all organisms in-
cluding humans except for their target bacterial hosts, infecting every
type of bacterium in every known environment and being among the
major drivers of bacterial adaptive evolution (Santos et al., 2014;
Brussow and Kutter, 2005; Chibani-Chennouﬁ et al., 2004; Brussow and
Hendrix, 2002; Bergh et al., 1989; McCallin et al., 2013; Abedon, 2015;
Pirnay et al., 2015). Due to both the vast number of bacteriophages and
the even larger number of unexplored genes that these metabolically
inert particles carry, research is of utmost importance to fully under-
stand and beneﬁt from the biology and biotechnological potential of
such entities. Bacteriophages are highly diverse and infect essentially
all bacteria on earth (Catalão et al., 2013). Their genomes encode
proteins that have been useful for biotechnology applications including
food safety diagnostics, antibiotherapy of infections caused by anti-
biotic-resistant bacterial strains, DNA delivery vehicles and many more
relevant technologies. Phages infect one bacterial cell, replicate, and
then new virions are released and infect another cell. As a consequence,
phages control bacterial population numbers, and on the other hand
they contribute to moving genes from one bacterium to another. The
study of bacteriophage particles provides insights into the evolution of
genomes, bacterial adaptative evolution, and the way DNA is expressed
and copied, and potentially sheds light on the development of new
biotechnology products. Worldwide, the unstoppable increase of bac-
terial resistance to conventional chemical antibiotics is becoming a
renewed driving force for bacteriophage (or phage) therapy, making
use of lytic phage particles, since these biological entities devoid of any
metabolic machinery do not possess aﬃnity to eukaryotic cells (Chan
and Abedon, 2012; Dąbrowska et al., 2005). Additionally, the utiliza-
tion of bacteriophage particles in phage-based vaccination is emerging
as one of the most promising preventive strategies, together with plant
and animal gene transfer methods, phage display-based selection for
biological aﬃnity molecules, bacterial biosensing devices, gene de-
livery, food biopreservation and safety, biocontrol of plant pathogens,
bioﬁlm control, surface disinfection, and corrosion control. The issue of
structural and functional stabilization acquires a special relevance in
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the context of phage particles. Since these are of proteinaceous nature,
stabilization from both structural and functional points of view is di-
rectly related to rigidiﬁcation of their three-dimensional structure
(Balcão and Vila, 2015). This is a critical feature that will be discussed
further below in this review paper.
1.1. Bacteriophage particles
Bacteriophages are viruses that infect solely bacterial cells, being
biological entities known for over a century. To answer the question
“what is life?”, bacteriophages were elected as the simplest and most
logical biological systems, with research based on them becoming the
cradle of molecular biology (Chibani-Chennouﬁ et al., 2004). Despite
all the basic biological research involving bacteriophages, a special
interest in bacteriophages has now re-emerged, viewing them as po-
tential alternatives and/or complements to conventional chemical an-
tibiotherapy mainly because of their high-speciﬁcity and unique prop-
erties to ﬁght multi-resistant bacterial strains (Summers, 2012; Rios
et al., 2016). Bacteriophages are (biological) entities totally devoid of
any metabolic machinery, thus being obligate intracellular parasites
requiring a bacterium for their replication via their genetic material,
taking over the biochemical machinery of the bacterial cells (Hyman
and Abedon, 2010; Hermoso et al., 2007; Skurnik and Strauch, 2006;
Kokjohn et al., 1991). Due to the important role that bacteriophages
play in inﬂuencing the evolution of bacterial genomes, also inducing
the development of bacterial pathogenicity, these metabolically inert
particles may provide potential tools to face the current antibiotic re-
sistance crisis (Chibani-Chennouﬁ et al., 2004). Over the last few years,
a clear shift from the reductionist approach focusing on selected bac-
teriophages in carefully controlled laboratory conditions, towards the
study of many diﬀerent bacteriophages in the complexity of real-life
situations can now be perceived. Indeed, bacteriophages harness the
potential to be utilized in many diﬀerent biotechnological applications,
ranging from human antibiotherapy to environment disinfection. The
vast majority of bacteriophages discovered so far interact with bacterial
cells that express speciﬁc membrane surface receptors. However, if a
bacterial cell does not expose a speciﬁc receptor for a particular bac-
teriophage at its surface, then the bacteriophage cannot infect it, which
demonstrates the naturally high speciﬁcity of a bacteriophage to a
particular bacterial host. Estimates suggest about ten diﬀerent bacter-
iophages for every bacterial cell, some of which are highly speciﬁc for
their bacterial host (either monophages (recognizing only one type of
receptor) or polyphages (displaying a broader host range and re-
cognizing more than one type of receptor)) (Skurnik and Strauch, 2006;
Hyman and Abedon, 2010; Chan and Abedon, 2012). From the mor-
phological point of view, bacteriophage particles exhibit a well-deﬁned
three-dimensional structure, the vast majority presenting an icosahe-
dral protein capsid enclosing the genetic material in its core, a spiral
contractile sheath (or tail) (surrounding a core pipe) and, usually, six
tail ﬁbers connected to a baseplate containing the receptor-binding
proteins responsible for recognizing speciﬁc molecules at the surface of
the bacterial membrane, as graphically illustrated in Fig. 1.
In relation to the type of genetic material they harness within the
capsid's core, bacteriophage particles can be divided into four major
groups (see Fig. 2): single stranded DNA phages (ssDNA), double
stranded DNA phages (dsDNA), single stranded RNA phages (ssRNA),
and double stranded RNA phages (dsRNA).
Over the last ﬁfty years, more than 5100 bacteriophages have been
identiﬁed and studied, with more than 90% of them possessing tails and
belonging to the Myoviridae, Siphoviridae and Podoviridae families
(Wittebole et al., 2013; Ackermann, 2007; Hanlon, 2007; Dąbrowska
et al., 2005) (see Table 1). More than 2200 complete bacteriophage
genomes can be found in the NCBI Genome database (as veriﬁed on
October 7th 2017).
1.1.1. Bacteriophage-bacterial host surface interactions
The baseplate in the bacteriophage three-dimensional structure
coordinates both bacterial host recognition and attachment, with tail
sheath contraction (if applicable), a movement initiated at the base-
plate and propagated through the entire sheath in a wave-like fashion.
Fig. 1. Schematic representation of a prototypical bacteriophage particle. The
bacteriophage DNA is protected by the icosahedral capsid, which is attached to
the contractile sheath, a highly specialized and extremely eﬃcient phage
component required for infecting its host. The hexagonally shaped baseplate is
situated at the distal end of the contractile sheath, and coordinates the move-
ment of the tail ﬁbers that initially sense the presence of the host, the short tail
ﬁbers that unfold from underneath the baseplate to ﬁrmly anchor on its bac-
terial host surface, and the spiral contractile sheath surrounding a core pipe that
contracts, ejecting DNA into the bacterial host.
Adapted from Rossmann et al. (2005).
Fig. 2. Classiﬁcation of bacteriophages according to their morphology, genetic
material and major characteristics.
Adapted from Ackermann (2007) and Hanlon (2007).
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The tail ﬁbers, extending from the bacteriophage baseplate, constitute
the primary determinants of bacterial host speciﬁcity (Leiman and
Shneider, 2012). The successful binding to a bacterial host receptor
triggers a conformational change in the baseplate that ultimately leads
to sheath contraction. Hence, the signal from binding to the bacterial
host must be transmitted through the entire ﬁber to the baseplate, a
transmission that occurs via changing the orientation of the ﬁbers re-
lative to the baseplate. When the bacteriophage particles are free in
(aqueous, buﬀer) solution, their tail ﬁbers do not exhibit a ﬁxed or-
ientation, pointing roughly sideways or even towards the capsid
(Leiman and Shneider, 2012). The bacteriophage particle's tail ﬁbers
bound to the surface of the bacterial host point towards it. Two possible
mechanisms for the bacteriophage infection of a speciﬁc bacterial host
have been accepted nowadays, explaining how and why such changes
in tail ﬁber orientation occur only on the bacterial host surface, but not
when the bacteriophage particle is free in (aqueous) solution (see
Fig. 3) and, remarkably, without any use of chemical energy in ﬁber
reorientation and baseplate triggering.
The ﬁrst postulated and most widely accepted mechanism is based
on the rationale that, when the bacteriophage particle encounters a
susceptible bacterial host, only one or two (at most) of its tail ﬁbers
bind to speciﬁc bacterial host surface receptors, hence subjecting the
attached bacteriophage particle to the inﬂuence of all solvent move-
ments originating from bacterial cell swimming and other types of
molecular motions (viz. Brownian, thermally induced, and convective-
current movements). The bacteriophage particle is now tethered to the
bacterial host via binding between its tail ﬁber(s) and speciﬁc receptors
on the surface of the bacterial host, while being constantly shaken by
the solvent (Leiman and Shneider, 2012). At a certain point, other tail
ﬁbers of the bacteriophage particle establish connections with other
receptors on the surface of the bacterial host, causing all the tail ﬁbers
to be pointed towards the surface of the bacterial host with concomitant
positioning of the bacteriophage particle perpendicular to the mem-
brane of the bacterial host. With the tail ﬁbers pointing towards the
surface of the bacterial host, more interactions are formed in the
baseplate causing it to switch to a lower free energy conformation,
unlocking the sheath and allowing it to contract (Inamdar et al., 2006).
However, spontaneous contraction of the tail does not occur, since the
orientations of the tail ﬁbers associated with both the extended and
contracted three-dimensional conformations of the sheath are separated
by a signiﬁcant variation in Gibbs free energy (ΔG). The only way to
overcome such high ΔG, with the tail ﬁbers immobilized on the surface
of the bacterial host, is for the bacteriophage particle to be constantly
agitated by the solvent movements (Leiman and Shneider, 2012;
Kostyuchenko et al., 2005; Leiman et al., 2004).
Another possible explanation for how bacteriophage tail ﬁber re-
orientation may be coupled to sheath contraction upon attachment of
the bacteriophage particle to the surface of the bacterial host arises
from the fact that many bacteriophage particles often require calcium
for infection of bacteria. Certain molecules on the surface of bacterial
cells (e.g. polysaccharides and proteins) bind divalent cations such as
calcium, greatly increasing their concentration in the immediate
neighborhood of the bacterial surface. Such a high concentration of
divalent cations may promote a change in the three-dimensional con-
formation of the baseplate with concomitant extension of the tail ﬁbers
so as to bind to the surface of the bacterial host, followed by unlocking
of the sheath. This second possible mechanism is similar to that pro-
posed by Sciara et al. (2010) for bacteriophage p2, speciﬁc for the
Gram-positive lactic acid bacterium Lactococcus lactis, whose infection
process requires calcium.
A further mechanism that may regulate phage ability to interact
Table 1
Major types of bacteriophages.
Modiﬁed from Ackermann, 2007).
Bacteriophage group Nucleic acid type Distinctive features of the virion Example
Myoviridae linear dsDNA contractile sheath/tail T4
Siphoviridae linear dsDNA non-contractile long and ﬂexible sheath/tail λ
Podoviridae linear dsDNA non-contractile short sheath/tail T7
Microviridae circular ssDNA isometric particles without sheath/tail &x3D5;X174
Corticoviridae circular dsDNA isometric particles without sheath/tail PM2
Tectiviridae linear dsDNA isometric bacteriophage particles without sheath/tail PRD1
Leviviridae linear ssRNA isometric bacteriophage particles without sheath/tail MS2
Cystoviridae enveloped segmented dsRNA spherical bacteriophage particles without sheath/tail &x3D5;6
Inoviridae circular ssDNA ﬁlamentous bacteriophage particles without sheath/tail fd
Plasmaviridae enveloped circular dsDNA pleomorphic bacteriophage particles without sheath/tail MVL2
Fig. 3. A putative mechanism for the bacteriophage-driven breaching of the
bacterial host envelope, during the infection process. The inserted arrows in
Fig. 3a, b, c and d indicate bacteriophage particle drifts (viz. Brownian move-
ments, thermally induced, convective currents) induced by solvent movement,
whereas the inserted arrows in Figs. 3e, 3f, 3 g and 3 h indicate the bacter-
iophage capsid movement (driven by sheath contraction) towards the bacterial
host surface. When the bacteriophage particle is free in aqueous solution (see
Fig. 3a) its tail ﬁbers move freely depending on solvent movement patterns;
upon approaching a bacterial host (see Fig. 3b), the bacteriophage particle
binds to its surface with one or two of its tail ﬁbers, a binding that functions as a
tether to restrict the movements of the bacteriophage particle; after the initial
tethering at the bacterial host's surface, the bacteriophage particle drifts in such
a way that the (already bound) tail ﬁber acquires a conformation (see Fig. 3c)
from which it cannot switch back to that of the free bacteriophage particle,
establishing new interactions with the baseplate proteins, and leading to in-
itiation of the baseplate three-dimensional conformational change; the bacter-
iophage particle continues its kind of a “hula–hula dance” on the bacterial host's
surface (see Fig. 3d), while being tethered to it via the bound tail ﬁber, and,
eventually, the other tail ﬁbers come into contact with their binding partners on
the bacterial host's surface; now that all of its tail ﬁbers are bound to bacterial
host's surface receptors, the bacteriophage drifts in such a way that all of its tail
ﬁbers point toward the host cell (see Fig. 3e), with the conformational change
of the baseplate continuing to proceed; The three-dimensional conformational
change of the baseplate initiates contraction of the sheath (see Fig. 3f), driving
the capsid and the tail tube toward the bacterial host's membrane, and the outer
bacterial host's membrane is punctured with the help of the baseplate central
spike protein; after puncturing the outer bacterial host's membrane, the spike
dissociates from the tail tube tip and opens the tail tube channel (see Fig. 3g),
with the tail-associated glycosidase creating a small opening in the pepti-
doglycan layer; in the ﬁnal stage of infection, the bacteriophage particle's tail
tube interacts with the bacterial host's inner membrane (see Fig. 3h), which is
further pushed toward the tail tube by the osmotic pressure of the cytoplasm in
the small region now lacking the peptidoglycan layer, and the bacteriophage
DNA is released within the bacterial host's cytoplasm.
Adapted from Inamdar et al. (2006) and Leiman and Shneider (2012).
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with the surface of bacteria is the ionic strength of an environment.
Szermer-Olearnik et al. (2017) identiﬁed ionic strength as a triggering
factor for bacteriophage virions aggregation/disaggregation. As de-
monstrated by scanning electron (SEM) and atomic force (AFM) mi-
croscopy, bacteriophage particles can form viral packages, each con-
taining 20-100 virions. In this form, bacteriophages show weakened
infectivity, but they are more likely resistant to environmental factors.
In a higher ionic strength solution, which is characteristic for the sur-
roundings of bacteria, bacteriophages disaggregate and restore their
full infectivity. Ionic ﬂuxes are typical for living bacteria, as part of
cation exchangers in bacterial membranes. Thus, bacteriophage parti-
cles are able to detect bacterial cells in their proximity and to change
their arrangement in a way that facilitates infection.
In fact, there is a possibility that all these mechanisms work at the
same time. As mentioned before, the tail ﬁbers become oriented to-
wards the surface of the bacterial host as a result of solvent-induced
bacteriophage drifts and, concomitantly, the baseplate becomes more
prone to a change in its three-dimensional conformation in the presence
of certain “surface-associated” ions. With sheath contraction the capsid
becomes closer to the surface of the bacteria, at the same time that the
tail tube protrudes from below the plane of the baseplate. The central
hub in the baseplate complex, onto which the tail tube is initially as-
sembled, is dislodged from the baseplate to form the tip of the tube.
This complex is the membrane-piercing “spike” that perforates the
bacterial outer membrane driven by the sheath's energy (Leiman and
Shneider, 2012) and allows the bacteriophage genetic material to exit
through the tail tube into the cytoplasm of the bacterium. The large
amount of energy stored in the folded conformation of capsid-packaged
bacteriophage DNA is not used in the bacterial membrane penetration
process. This principle is supported by observations of tailocins, i.e.
bactericidal proteins resembling bacteriophage tails that are functional
without an associated phage head. They are able to disrupt the bacterial
envelope with concomitant cell death as DNA-free complexes (Scholl
et al., 2009; Ghequire and De Mot, 2015). Also, tail sheath contraction
and DNA ejection phenomena are not linked, since bacteriophages with
contracted tails can be fairly stable and do not release their DNA
(Leiman et al., 2004). Hence, it can be hypothesized that the bacterial
cytoplasmic membrane must contain a speciﬁc receptor, at least as
abundant as the bacteriophage receptor on the bacterial surface, for
opening up the bacteriophage tail tube and triggering DNA release. The
tail tube channel opening is likely to be triggered by certain lipid mo-
lecules within the cytoplasmic membrane, with translocation of bac-
teriophage DNA into the bacterial host through the tail tube being the
next step in the infection process.
As discussed above, bacterial infection by its natural predator
(bacteriophage) is initiated when the bacteriophage particle(s) is ad-
sorbed onto the surface of its bacterial host (Shao and Wang, 2008;
Dąbrowska et al., 2005). After the initial contact between the bacter-
iophage particle(s) and bacterium (Smith and Trevino, 2009), via dif-
fusion and Brownian motion, the bacteriophage particle establishes
reversible and nonspeciﬁc binding to the bacterium surface mainly via
electrostatic forces, followed by irreversible binding between the bac-
teriophage's capsid protein and a bacterial surface receptor which, de-
pending on the type of bacteriophage, may be: (i) a glycoprotein, (ii) a
lipopolysaccharide, (iii) an amino acid, (iv) a teichoic acid, or (v) pili
(Wittebole et al., 2013; Maura and Debarbieux, 2011; Shao and Wang,
2008; Skurnik and Strauch, 2006; Miernikiewicz et al., 2016).
1.1.2. Bacteriophage-induced degradation of the host cell’s envelope
components
The onset of the bacterial cell infective process by the bacteriophage
particles is hampered by the need to penetrate through a complex
bacterial host cell envelope, a multilayered structure that protects these
organisms from their unpredictable and often hostile environment. The
bacterial cell envelope falls into one of two major categories. The en-
velope of Gram-negative bacterial cells usually encompasses an inner
cell membrane, a thin periplasmic peptidoglycan layer and an outer
membrane containing lipopolysaccharides (LPS). The envelope of
Gram-positive bacterial cells lacks an outer membrane, but it possesses
a much thicker peptidoglycan layer densely functionalized with long
anionic glycopolymers called wall teichoic acids (Silhavy et al., 2010).
In addition, many bacteria express an outermost protective coat, the S-
layer, which is composed of a single protein that totally encases the
organism, or these cell-envelope structures may be surrounded by other
protective structures such as capsular polysaccharides (e.g. α-2,8-linked
polysialic acid (PSA) and/or hyaluronic acid (HA)), or mycolic acids
(Silhavy et al., 2010). Bacteriophage virions must therefore be
equipped with tools that allow them to penetrate through all these
protective layers. Hence, bacteriophages carry enzymes capable of
perforating the capsule and peptidoglycan layer(s) of their speciﬁc
bacterial hosts (Rodríguez-Rubio et al., 2016; Salmond and Fineran,
2015; Moak and Molineux, 2004). Bacteriophage virions that bind to
lipopolysaccharides (LPS) usually degrade these polysaccharide chains
immediately following attachment. Pires et al. (2016) presented an
extensive review on the diversity of bacteriophage-encoded depoly-
merases, used by bacteriophages to overcome bacterial protective
layers and thus reach the bacterial cytoplasm.
1.1.2.1. Bacteriophage-induced degradation of the bacterial host
capsule. Many bacterial cells are protected by a network of
polysaccharides globally called the glycocalyx, a carbohydrate-
enriched coating that covers the outside of many eukaryotic and
prokaryotic cells, particularly bacteria, comprised of tiny viscous
ﬁbers. When loosely covering the outer surface of bacterial cells, such
a network is called a slime layer, facilitating bacterial movement. When
it is in a condensed form that is relatively tightly associated with the
underlying cell wall, the glycocalyx is referred to as a capsule. There are
two main functions of the glycocalyx. The ﬁrst is to enable bacteria to
become more diﬃcult for the immune cells (phagocytes) to surround
and engulf, since the presence of a glycocalyx increases the eﬀective
diameter of a bacterium and it also covers up components of the
bacterium, thus making it less “visible” and less stimulatory for the
immune systems of animals and humans.
The second function of a bacterial glycocalyx is to promote the
adhesion of the bacteria to living and inert surfaces, with the sub-
sequent formation of adherent, glycocalyx-enclosed bacterial ag-
gregates commonly referred to as bioﬁlms. Bacteria in bioﬁlms can
become resistant to a variety of antibacterial factors, partly due to the
presence of the glycocalyx material. Many persistent infections in the
human body can be attributed to bacterial bioﬁlm formation. Examples
are chronic lung infections in patients aﬄicted with certain forms of
cystic ﬁbrosis and infected with glycocalyx-producing Pseudomonas
aeruginosa (Glonti et al., 2010). The glycocalyx layer (with a thickness
≥400 nm) protects the cell from hostile environments and, at the same
time, prevents bacterial viruses from reaching their entry receptor at
the cell surface (Bazaka et al., 2011). Bacteriophages that infect bac-
terial cells encompassing a capsule (condensed glycocalyx tightly as-
sociated with the underlying cell wall) carry exopolysaccharide (EPS)-
degrading enzymes (depolymerases) in their tail spikes. These enzymes
allow bacteriophages to hydrolyze the bacterial outer sugar coat so that
they can reach either the outer membrane or the peptidoglycan layer
(Yan et al., 2014; Cornelissen et al., 2012). The glycocalyx-based bac-
terial capsule can be composed of various EPS, such as alginates,
polysialic acids (PSAs) and hyaluronic acid (HA), whereas EPS depo-
lymerases include enzymes such as glycanases, lyases and capsule-
speciﬁc deacetylases.
1.1.2.2. Bacteriophage-induced degradation of the bacterial host
lipopolysaccharides. Some bacteriophage particles contain enzymes
able to hydrolyze the lipopolysaccharides (LPS) of Gram-negative
bacteria, an enzymatic activity that is often associated with the tail
spike proteins. LPS hydrolysis is likely a strategy utilized by the
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bacteriophage particles to clear a path through the bacterial LPS, thus
allowing them to gain access to the entry receptor(s) on the bacterial
cell surface. On the other hand, and very interestingly, LPS-degrading
bacteriophages can also use LPS as attachment receptors, and thus LPS
degradation may act to release bacteriophage progeny particles from
bacterial cell debris at the end of a lytic cycle (Drulis-Kawa et al., 2012).
EPS depolymerases include enzymes such as LPS-speciﬁc glycanases
and LPS-speciﬁc deacetylases.
1.1.2.3. Bacteriophage-induced degradation of the bacterial host
peptidoglycans. Endolysins are the lytic enzymes used by phages at
the end of the replication cycle to degrade bacterial peptidoglycan (PG)
from within, resulting in a rapid host lysis and the release of phage
progeny. Virion-associated lysins (VALs) and depolymerases are linked
to the virion particle and serve at the beginning of infection to
overcome bacterial cell surface barriers. VALs are responsible for PG
degradation required for phage genetic material injection to the
infected host cell, whereas depolymerases degrade polysaccharide
molecules such as capsule, lipopolysaccharide (LPS), or bioﬁlm
matrix (Casey et al., 2018; Maciejewska et al., 2018; Criscuolo et al.,
2017; Drulis-Kawa et al., 2015; Drulis-Kawa et al., 2012; Meng et al.,
2011b; O'Flaherty et al., 2009). This hydrolytic activity is necessary for
the bacteriophage to reach the bacterial host plasma membrane and
inject its genetic material into the host's cytoplasm. Such hydrolysis is
local, with the virion drilling a hole large enough to have its tail or
sheath pass the cell wall. Depending on the enzymatic speciﬁcity,
bacteriophage lysins (murein hydrolases) are divided into ﬁve main
classes: (i) lysozymes (N-acetyl-β-D-muramidases), (ii) lytic
transglycosylases, (iii) N-acetyl-muramoylamidases, (iv) N-acetyl-β-D-
glucosaminidases, and (v) endopeptidases.
1.1.3. Lytic and lysogenic modes of action
Subsequently to the binding of the bacteriophage particle to the
bacterium surface, a spike at the bottom of the baseplate in the bac-
teriophage structure penetrates into the bacterial host, followed by a
complete release of the bacteriophage’s genetic material into the host’s
intracellular environment.
Either a lytic (see Fig. 4a) or a lysogenic (see Fig. 4b) cycle can take
place following bacterial infection, depending on the type of bacter-
iophage. Considering the lytic pathway, promoted by strictly lytic
bacteriophages (also commonly termed virulent bacteriophages), the
bacterial host’s metabolic machinery is taken over and re-targeted to
the production of new bacteriophage particles. This encompasses re-
plication of the bacteriophage genome in the bacterial cytoplasm with
concomitant synthesis of viral proteins (viz. capsid, tail) and assembly
of more lytic bacteriophage virions in cycles of ca. 30min each which,
with the help of bacteriophage-synthesized holins and lysins, causes
lysis of the bacterium (see Fig. 4a) (Dąbrowska et al., 2005) and re-
leases a wave of newly formed virions. Simply put, the bacteriophage
particle hijacks the bacterium, turning it into a bacteriophage-produ-
cing factory. To facilitate this, genomes of many bacteriophages are
natively methylated by a DNA adenine-methylase that introduces me-
thyl groups in the carbon 5 of the pyrimidine ring in cytosine residues.
Methylation protects exogenous bacteriophage DNA from the destruc-
tive restriction endonucleases encountered in the bacterial cytoplasm
(Wittebole et al., 2013; Maura and Debarbieux, 2011; O'Flaherty et al.,
2009; Dąbrowska et al., 2005; Weinbauer, 2004).
The lysogenic cycle (see Fig. 4b) characteristic for temperate bac-
teriophages is a cycle with delayed propagation of the bacteriophage,
since the viral genome becomes integrated within the bacterial genome.
In this case, the bacterium becomes immune to attacks of other bac-
teriophage particles of the same strain. This may potentially make
bacteria more virulent and resistant to some bacteriophages (Wittebole
et al., 2013; Maura and Debarbieux, 2011; O'Flaherty et al., 2009;
Weinbauer, 2004). Such a lysogenic bacterium contains an integrated
prophage in its genome, and the prophage remains in a latent state even
in many bacterial cell divisions, until it is activated by stress or cellular
damage processes of the bacterial host. These factors turn the bacter-
iophage cycle to the replication via a lytic pathway (after excision from
the bacterial genome) with concomitant release of the new virions
(Wittebole et al., 2013; Maura and Debarbieux, 2011; Lu and Collins,
2009; Hanlon, 2007; Weinbauer, 2004).
In either the lytic or lysogenic cycle, after the intracytoplasmic
synthesis of the bacteriophage proteins and enzymes responsible for
both capsid formation and genome packaging, the assembly and for-
mation of new virions occurs. To release newly formed virions, the cell
membrane is disrupted by holins that perforate the membrane and fa-
cilitate translocation of lysins to the peptidoglycan layer (importantly,
holins are products of the “old” bacteriophage particles since they are
expressed from their genome; newly formed virions do not do it).
Peptidoglycan is degraded, leading to lysis of the bacterium with con-
comitant expulsion of the newly formed virions to the extracellular
environment (Wittebole et al., 2013; Maura and Debarbieux, 2011;
Smith and Trevino, 2009; Ackermann, 2007).
1.1.3.1. Bacteriophage inter-particle communication for death or
salvation. As stated above, temperate bacteriophage particles may
become dormant in their host bacterial cells, in a process called
lysogeny. In every infection cycle, such particles have to “decide”
between lytic and lysogenic cycles, i.e., whether to replicate and lyse
their host, leading to its death, or to lysogenize and keep the host viable
(Erez et al., 2017). Here a question arises: how does a bacteriophage
particle “know” when to kill or save an infected bacterial host cell? The
mechanism of this decision has long been unclear but, in a very recent
study by Erez et al. (2017), a mechanism for how bacteriophage
particles make such a decision has been reported. It is actually a form
of inter-virus communication (Davidson, 2017; Erez et al., 2017;
Gerritsen, 2017). Using Bacillus subtilis as a model, these researchers
identiﬁed a small-molecule communication system involving a
hexapeptide moiety released into the medium that appeared to
protect bacterial cells from lysis after infection by a bacteriophage
particle. In fact, such peptide (called arbitrium by Erez et al. (2017))
turned out to originate from bacteriophages after they entered a
lysogenic cycle, and instead of protecting bacteria per se, it directed
other bacteriophage particles to lysogenic instead of lytic cycles. This
arbitrium system enables a descendant bacteriophage virion to
“communicate” with its predecessors, that is, to estimate the amount
of recent previous infections and hence decide whether to employ the
lytic or lysogenic cycle (Erez et al., 2017; Gerritsen, 2017). This is,
ultimately, the ﬁrst known mechanism of intracellular communication
between viral particles, and may be a way for these bacterial viruses to
continue infecting future generations of bacteria. It turns out that, when
a bacteriophage particle is faced with the problem of how to infect a
bacterial cell, natural selection prevails (Erez et al., 2017). The
biological rationale behind this arbitrium system is in fact quite clear:
when a single bacteriophage particle encounters a susceptible bacterial
colony, there exists ample prey for the bacteriophage progeny produced
from the ﬁrst lytic cycles of infection. However, the number of viable
bacterial cells is reduced in each lytic cycle to a level where newly
released bacteriophage virions are at risk of no longer having a
bacterial host to infect. According to Abedon (2017), bacteriophages
extend their infections presumably to more fully exploit increasingly
rare bacterial host cells, using either lysogenic cycles or lysis inhibition.
Therefore, it is logical for bacteriophages to switch into lysogeny to
preserve their chances for viable reproduction. Hence, the arbitrium
system provides an elegant mechanism for a bacteriophage particle to
estimate the number of recent prior infections and decide whether to
pursue the lytic or lysogenic pathway. Regulation of lytic-lysogenic
cycles in phages may have a profound impact on the possibility to use
some phage strains for therapeutic purposes. Speciﬁcally because in
some important (for therapeutic applications) phage groups still no
obligatory lytic phages have been found, e.g. for C. diﬃcile phages.
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2. Structural and functional stabilization issues
The issue of structural and functional stabilization acquires a special
relevance in the context of bacteriophage particles, if these metaboli-
cally inert proteinaceous entities are to be utilized in any biotechno-
logical applications. Since they are of proteinaceous nature, stabiliza-
tion from both structural and functional points of view is directly
related to rigidiﬁcation of their three-dimensional structure (Balcão and
Vila, 2015). Attachment or embedment of a protein entity such as a
bacteriophage particle in any solid matrix promotes a change in the
water activity of its immediate (and surrounding) nanoenvironment,
within which the motions of (any) water molecules are so restricted that
they do not crystallize even at very low temperatures but instead
transition into a highly viscous state, stabilizing the protein entities by
hyper-increasing their rotational, translational and vibrational viscos-
ities. Overall, the thermodynamic (or conformational) stability of the
bacteriophage particle can be correlated with a change in the thermo-
dynamic conditions of the nanoenvironment surrounding each (bio)
particle, since the movements of (aqueous) solvent molecules in their
immediate vicinity become seriously reduced. Because there is a direct
relationship between the molecular motions of a protein entity and the
molecular motions of its immediate vicinity, when we attach a (bio)
particle such as a bacteriophage onto a solid matrix we are virtually
eliminating the motions of the (aqueous) solvent molecules in its im-
mediate vicinity (thereby increasing the bacteriophage particle’s rota-
tional, translational and vibrational viscosity), leading to a more rigid
three-dimensional architecture with concomitant decrease of entropy
and producing stabilization (Balcão and Vila, 2015).
3. Phage therapy
We currently face a dramatic increase in the levels of bacterial re-
sistance to conventional antibiotherapy, with a real danger of entering a
new “pre-antibiotic era”. According to the World Alliance against
Antibiotic Resistance (WAAR), conventional antibiotics are on the brink
of completely losing their eﬀectiveness, mostly due to a combination of
self-medication, irrational prescription and overuse. These factors have
led to the emergence of multi-resistant bacterial strains, even those
resistant to all currently available antibiotics (Rios et al., 2016; Kutter
et al., 2015; Kaźmierczak et al., 2014). The increased use of antibiotics
is partially related to the growing numbers of people needing health-
care, as a result of population ageing with concomitant increase of
chronic diseases and healthcare-associated infections (Fair and Tor,
2014). The overuse of antibiotics in humans leads to selection of re-
sistant bacterial specimens also from the normal microbiota, hence
contributing to environmental dissemination of resistance genes
(Nitsch-Osuch et al., 2016). Additionally, the overuse of antibiotics for
therapeutic, prophylactic or growth-promoting purposes in farm ani-
mals induces further the selection of pathogenic and/or commensal
bacteria resistant to antibiotics (Aarestrup, 2015; Boerlin and Reid-
Smith, 2008; Donabedian et al., 2003; Wegener, 2003; Aarestrup et al.,
2000). Subtherapeutic dosages induce phenotypic changes in bacteria
contributing to the emergence of bacterial resistance (Viswanathan,
2014).
Klebsiella pneumoniae carbapenemase (KPC), an enzyme that de-
grades carbapenem antibiotics, was historically largely associated with
Klebsiella pneumoniae, and later isolated from E. coli all over the world
(Liu et al., 2016; Nordmann et al., 2011; Stoesser et al., 2017). The
ways pathogenic bacteria can resist to antibiotics are related to dif-
ferent mechanisms of resistance, namely (i) a marked decrease in
bacterial uptake of the antibiotic molecule, (ii) production of hydro-
lases (e.g. β-lactamases) that inactivate the antibiotic, (iii) modiﬁcation
of the antibiotic receptor, (iv) a marked decrease in the intracellular
concentration of the antibiotic by means of eﬄux pumps present in the
bacterial membranes, (v) alteration of the enzymatic pathway(s) with
concomitant decrease of bacterial susceptibility to the antibiotic, and
(vi) deprivation of the intracellular enzymes needed for activation of
prodrug(s) (Rios et al., 2016; Ojala et al., 2013; Rouveix, 2007; Stavri
et al., 2007; Piddock, 2006).
The Gram-negative bacterium Pseudomonas aeruginosa, which can
Fig. 4. Schematic diagram of the lytic (a) and
lysogenic (b) infectious cycles of a bacterial
predator (i.e. a bacteriophage). The process of
bacterial infection by its predator begins when
the bacteriophage adsorbs onto the surface of
its bacterial host cell in a complex process.
There is initially a contact between bacter-
iophage and bacterium by diﬀusion and
Brownian motion after which the bacteriophage
particle establishes reversible, nonspeciﬁc
binding via electrostatic forces, followed by ir-
reversible binding between the capsid protein
of the bacteriophage particle and speciﬁc re-
ceptors on the bacterial surface. After binding
of the bacteriophage to the bacterial cell sur-
face, a portion of its structure penetrates into
the bacterial host followed by a complete ejec-
tion of the genetic material into the host’s in-
tracellular environment. Depending on the type
of bacteriophage, either a lytic or a lysogenic
cycle can occur following bacterial infection. In
the lytic response (promoted by strictly lytic
bacteriophages), the metabolism of the bac-
terial host is assaulted and re-targeted to the
production of new bacteriophage particles, by
replicating the genetic material of the virus into
the cytoplasm, leading to the synthesis of more
lytic bacteriophage particles which, aided by
produced holins and lysins, subsequently causes
lysis of the bacterium. In the lysogenic response (promoted by temperate bacteriophages), the bacteriophage replication occurs at a later stage (since the viral genetic
material is integrated into the genome of the bacterium) and the bacteriophage is replicated without lysing the host, with the bacterium becoming immune to attacks
of other bacteriophages of the same strain (becoming a lysogenic, and usually more virulent, bacterium).
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infect a wide range of animal and plant hosts, has become a superbug
(Breidenstein et al., 2011). Krylov et al. (2016) extensively reviewed
the potential applications of bacterial viruses (bacteriophage therapy)
aimed at eradication of antibiotic-resistant Pseudomonas aeruginosa in
children with cystic ﬁbrosis (CF). A transmissible plasmid has been
isolated encoding MCR-1, an enzyme that transforms the bacterial lipid
A in the outer membrane to a colistin-resistant state (Liu et al., 2016).
This plasmid has been found in Escherichia coli strains, but given the
relative ease of interspecies plasmids migration, it was almost in-
evitable that some strains of Pseudomonas aeruginosa infecting patients
with CF would acquire additional transmissible resistance to colistin.
Hence, the increased reliance on colistin for treating multidrug-re-
sistant Gram-negative bacterial infections has resulted in the emergence
of colistin-resistant Pseudomonas aeruginosa (López-Causapé et al.,
2017; Lee et al., 2016b). The mechanisms through which Pseudomonas
aeruginosa acquires and loses resistance to colistin have implications for
the treatment options that can be applied against Pseudomonas aerugi-
nosa infections, with respect to improving bactericidal eﬃcacy and
preventing further resistance to antibiotics.
These facts clearly demonstrate the need for developing eﬀective
and viable alternatives to current chemical antibiotherapy, aimed at
protecting and promoting planetary public health (Rios et al., 2016;
Dąbrowska et al., 2014; Oldﬁeld and Feng, 2014; WHO, 2015). New
actions and alternative strategies should thus be implemented not only
at the community level but also at health care centers. Bacteriophages
are natural antimicrobials that hold the potential to serve as viable
alternatives to conventional antimicrobial chemotherapy (Dąbrowska
et al., 2014; Pirnay et al., 2012; Cairns et al., 2009; Górski et al., 2016).
The use of bacteriophages in the treatment of bacterial infections pre-
sents numerous advantages over treatment with conventional anti-
biotics. First, bacteriophage treatment does not interfere with the
normal microbiota because it is highly speciﬁc. Second, bacteriophage
treatment does not require successive administrations of the agent, as
the bacteriophage begins to replicate on its own in the host and ceases
its action when its host no longer exists. At that point, therapeutic
success is achieved by virtue of the extinction of the etiological agent
(Shlezinger et al., 2017). In the Republic of Georgia (the Eliava Institute
and the Center for Phage Therapy, in Tbilisi) and in Poland (the In-
stitute of Immunology and Experimental Therapy, in Warsaw), bac-
teriophage therapy has been extensively (and successfully) applied over
the last decades in the treatment of bacterial infections (compassionate
use) (Kutter et al., 2010; Górski et al., 2016). Notwithstanding the
immense potential of bacteriophages for eradicating infections caused
by antibiotic-resistant bacterial strains, only a limited number of clin-
ical trials have been authorized by public health authorities (such as the
US Food and Drug Administration (FDA) and European Medicines
Agency (EMA)) and performed so far in humans. The issues related to
therapeutic use of bacteriophages and bacteriophage registration have
been recently extensively discussed by several authors from the ﬁeld of
bacteriophage therapy (Maura and Debarbieux, 2011; O'Flaherty et al.,
2009; Debarbieux et al., 2016; Górski et al., 2016; Sarker and Brüssow,
2016).
3.1. Phage kinetics and phage dynamics
The pharmacokinetics of bacteriophages (herein proposed as “phage
kinetics”) describes the amount of bacteriophage particles available in a
living system with its changes within time. Pharmacodynamics of
bacteriophages (herein proposed as “phage dynamics”), in turn, de-
scribes and measures the physiological eﬀects that bacteriophages exert
in a living system. Phage kinetics and phage dynamics are interrelated
with one another. They represent the reciprocal interactions and impact
that the human or animal body may have with a bacteriophage in a
therapeutic action, being crucial for our understanding of therapeutic
failures or successes. However, the paradigms associated with therapies
based on conventional antibiotics cannot easily be transferred to
bacteriophage-based therapies, which has partially contributed to
problems with the acceptance of bacteriophagess as substitutes for
antibiotics. In particular, predictions of certain threshold phenomena
not normally encountered in the pharmacokinetics and pharmacody-
namics of conventional antibiotics play a central role in bacteriophage
therapy (Cairns et al., 2009). Phage kinetics and phage dynamics are
more complex than “classic” drug pharmacokinetics, since bacter-
iophages propagate throughout bacterial host populations. The bac-
teriophage mode of spreading throughout macrobiological populations
is similar to epidemics: they infect susceptible bacterial host cells, re-
plicate (which also means that they multiply), and subsequently infect
other susceptible bacterial host cells (Cairns et al., 2009). In the same
way, the rate of bacteriophage propagation is completely dependent on
the bacterial host population, since the bacteriophage population can
only increase in the presence of suﬃciently high numbers of bacterial
host cells.
One should be aware that in vitro replication of bacteriophages may
be quite diﬀerent from what actually occurs in vivo, due to many factors
that cannot be eﬀectively transferred from a living organism to in vitro
systems. In addition, the in vivo “phage kinetics” and “phage dynamic”
processes change according to the bacteriophage particle in question.
Hence, phage kinetics in phage therapy is dependent on several critical
parameters: (i) adsorption rate; (ii) latency period; (iii) initial bacter-
iophage dosage; (iv) time point; (v) clearance rate of the bacteriophage
particles from the body ﬂuids; (vi) ability of the phage to replicate in
situ including bacterial potential to form phage resistance; (vii) animal
or human anatomophysiology; (viii) environmental conditions; and (ix)
phage distribution in the human body, including speciﬁc eﬀects of the
immune system (Skurnik and Strauch, 2006; Dąbrowska et al., 2006;
Payne and Jansen 2001; Levin and Bull, 2004; Hodyra-Stefaniak et al.,
2015).
These universal factors can work diﬀerently in diﬀerent routes of
application. Dosing can be topical, or parenteral, or via per os delivery.
The goal is to achieve relatively high bacteriophage particle con-
centrations within the immediate vicinity of infecting bacteria. To be
eﬀective, bacteriophages must adsorb to bacteria and successfully infect
a large fraction of bacterial cells in order to clear bacterial infection.
3.2. Inhalational delivery of bacteriophages
Pulmonary infections are among the most common antibiotic-re-
sistant infections (Rios et al., 2018; Balcão et al., 2014a; Matinkhoo
et al., 2011). Bacteriophages capable of combating these infections
have been tested in vitro and in animal models, showing promising re-
sults, especially when the phages are administered via nebulization in
aerosol form (Borie et al., 2009; Cao et al., 2015; Carmody et al., 2010;
Cooper et al., 2014; Golshahi et al., 2011; Saussereau et al., 2014;
Henry et al., 2013). In respiratory tract infections, antibacterial agents
such as bacteriophages and antibiotics, can be administered locally to
the lung tissues as aerosols. This allows for higher concentrations at the
site of infection, avoiding dispersion of antibacterial agents in other
sites where such activity is not necessary, thus signiﬁcantly increasing
their activity in situ and reducing potential adverse eﬀects (Rios et al.,
2018; Balcão et al., 2014a; Golshahi et al., 2011; Matinkhoo et al.,
2011). In the year 2008, the use of a commercial bacteriophage pre-
paration (Pyophage) in a 5-year-old child diagnosed with cystic ﬁbrosis
who did not respond to standard antibiotic treatment was reported. The
infection was associated with the presence of P. aeruginosa and S.
aureus. The treatment was applied as nasal phage nebulization three
times per day. After six days of treatment, the overall condition of the
child improved signiﬁcantly, and after twenty days of treatment a
weight gain (1 kg) was observed, whereas no weight gain had been
observed for a year before the treatment. After 3 courses of treatment,
the last of which included tetracycline, S. aureus and P. aeruginosa were
undetectable in the sputum (Kutateladze and Adamia, 2008). This is in
line with the fact that antibacterial activity of Pseudomonas
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bacteriophages was demonstrated in vitro in sputum of cystic ﬁbrosis
bacteriophages (Saussereau et al., 2014).
In an animal model, Morello et al. (2011) isolated multi-resistant P.
aeruginosa from a patient with cystic ﬁbrosis and inoculated mice in-
tranasally with the bacteria to induce pneumonia. The progress of the
infection was assessed by quantiﬁcation of bacteria, inﬂammatory
markers, and cytotoxicity (cell death and lysis) levels. The P3-CHA
bacteriophage was used. Two doses (3.0× 107 and 3.0× 108 plaque-
forming units [PFU] per mouse) of bacteriophage were tested in ani-
mals that received lethal doses of P. aeruginosa. Twenty hours after the
start of treatment, the number of bacteria was quantiﬁed; it decreased
by more than two orders of magnitude in the high bacteriophage dose-
treated group when compared to the group that received no treatment.
There was also a strong reduction of cytokines and lactate dehy-
drogenase (a cell death marker) in the bacteriophage-treated group in
comparison to the group that received no treatment. The same favor-
able results were found in histological analyses of the animals’ lungs.
Intranasal aerosol of the same bacteriophage when applied prior to
infection was used to prevent pneumonia. Immunohistochemistry of
lungs from mice pre-treated with P3-CHA bacteriophages gave results
that were similar to those observed after curative treatment (Morello
et al., 2011).
Another group of pathogens that signiﬁcantly aﬀects cystic ﬁbrosis
patients is the Gram-negative Burkholderia cepacia complex (BCC). Two
anti-BCC bacteriophages (KS4-M and F фKZ) were lyophilized and
tested against BBC and P. aeruginosa in an in vitro model. These bac-
teriophages were found to be active and could disperse as an aerosol.
Thus, lyophilization should facilitate the delivery of bacteriophages via
inhalation (Golshahi et al., 2011). Also, other bacteriophages and
bacteriophage cocktails (KS4-M, KS14, фKZ/D3 and фKZ/D3/KS4-M)
were lyophilized and demonstrated as viable and appropriate for dis-
persion as aerosols (Matinkhoo et al., 2011). In an animal model of
pneumonia caused by BBC (B. cepacia complex-K56-2) in im-
munocompromised mice, the authors tested the activity of the KS-12
bacteriophage that was administered intraperitoneally or as an aerosol.
The aerosol therapy was much more eﬀective in treating pneumonia
than intraperitoneal administration. In a study by Semler et al. (2014),
a conclusion that aerosol-based phage therapy appears to be an eﬀec-
tive method for treating highly antibiotic-resistant bacterial respiratory
infections, including those caused by BCC bacteria, was reached. An-
other study was conducted in 2015 to evaluate phage therapy against P.
aeruginosa hemorrhagic pneumonia in vitro and in vivo in minks; in this
study atomization of phage preparations by ultrasonic treatment was
investigated. The authors used a lytic Podoviridae phage: vB_PaeP_PPA-
ABTNL (PPA-ABTNL) isolate from hospital sewage. The phage was
tested against ﬁve strains of P. aeruginosa that were isolated from minks
with hemorrhagic pneumonia. In vitro testing showed that the phage
was very eﬀective in destroying the bacteria. The phage also proved to
be very safe in subsequent in vivo tests performed in rats. The experi-
ment again showed the possibility of using this route of administration
to combat pneumonia caused by this microorganism (Cao et al., 2015).
Recently, Krylov et al. (2015) tackled the conditions for the safe,
long-term use of phage therapy against various infections caused by
Pseudomonas aeruginosa, describing how to select the most suitable
phages, their most eﬀective combinations and some approaches for the
rapid recognition of phages unsuitable for use in therapy against this
pathogen. The beneﬁts and disadvantages of the various diﬀerent ap-
proaches to the preparation of phage cocktails were also considered by
these researchers, together with the speciﬁc conditions required for the
safe application of phage therapy in general hospitals and the possibi-
lities for the development of personalized phage therapy. More re-
cently, Krylov et al. (2016) discussed the potential application of bac-
teriophages aimed at the eradication of antibiotic-resistant Pseudomonas
aeruginosa in children with cystic ﬁbrosis (CF).
Enteric Salmonella is a major problem in the production of poultry
and eggs (Mead, 2000). Measures such as antibiotics, probiotics and
vaccination are often used without the expected success (Borie et al.,
2009). A novel approach to the use of phages as a coarse spray was
proposed by Borie et al. (2009). Bacteriophages alone and in combi-
nation with probiotics were used to combat Salmonella enteritidis in
infected chickens. Three experimental groups were tested: bacter-
iophages speciﬁc for S. enteritidis were used in group I, probiotics (En-
terococcus spp. (1.0× 109 colony-forming units [CFU]/g), Lactobacillus
spp. (2.3× 107 CFU/g), and nonpathogenic coliform bacteria
(4.4× 109 CFU/g) were used in group II and a combination of bac-
teriophages and probiotics was used in group III. The chickens were
infected with S. enteritidis and administered one of the three treatments,
with both probiotics and bacteriophages administered via coarse spray.
The results showed that the group that received only probiotics showed
a reduced infection rate of 75.7% (compared to the control group,
which had an infection rate of 100%). The bacteriophage-treated group
exhibited a reduced infection rate of 80%. However, the combination of
the two agents reduced the infection rate to only 38.7% (p < 0.0001).
Phage spray was also used in experimental E. coli infections in
chickens, where two bacteriophages (designated SPR02 and DAF6)
were used against poultry isolates of E. coli. The infection was induced
by a relatively low dose of bacteria (104 CFU per bird injected into the
thoracic air sac). The mortality of birds was signiﬁcantly reduced (from
50% to 20%) when phages were given immediately after the challenge
but had little treatment eﬃcacy when administered 24 h or 48 h after
the challenge (Huﬀ et al., 2003). Bacteriophages were also eﬀective
when applied before bacteria, i.e. they had a good protective eﬀect
(Huﬀ et al., 2002). Later, however, the same group found that neither a
coarse nor a ﬁne spray protected birds from infection induced by in-
tratracheal (IT) challenge with E. coli in a higher dose: 108 CFU per
bird. Eﬀective protection was achieved when bacteriophage was also
administered intratracheally. This suggests that, at least in some
models, administration of bacteriophages to the site of a bacterial in-
fection is more eﬀective than a spray. The authors propose that this
decided the positive eﬀect of phage treatment (IT) or its lack (spray)
(Huﬀ et al., 2013).
3.3. Gastrointestinal application of bacteriophages
Bacteriophage count in the human gut is estimated at 1015 particles
(Dalmasso et al., 2014), which probably represents the highest con-
centration of biological entities on Earth. The three most abundant
virus families in the human gut are Siphoviridae, Myoviridae and Podo-
viridae (Babickova and Gardlik, 2015). As in any natural environment,
there is an ecological interplay between elements of the gut microbiota,
so bacteriophages inﬂuence the microbial community and its relation-
ships with the human host very strongly (Lucas Lopez et al., 2017).
Early reports of phage therapy in enteric infections came from the
Eliava Institute of Bacteriophages, Microbiology and Virology at the
Republic of Georgia in the 1930s. Early reports of the use of bacter-
iophages showed good results in ﬁghting cholera infections in India and
Eastern Europe. Although the scientiﬁc reports from that time are few
and poor, reports on prophylactic bacteriophage treatment against
dysentery in Soviet soldiers reveal a 10-fold lower incidence of dysen-
tery episodes in comparison to soldiers who did not receive phage
therapy (Kutter et al., 2010). Other reports of clinical use in civilians in
Georgia evaluated tableted phage therapy against dysentery in more
than 30,000 children in the 1960s. The treated and control groups were
separated based on the street on which they lived (i.e., on one side of
the street, the children were treated with phage therapy, while the
children across the street received placebo). The results showed a 3.8-
fold reduction in episodes of dysentery among treated children (Kutter
et al., 2010).
IntestiPhage preparations are cocktails of bacteriophages that are
used for the treatment and prophylaxis of intestinal infections caused
by Shigella, Salmonella, Proteus, Staphylococcus, E. coli and Pseudomonas.
In 2008, Kutateladze and Adamia reported interesting results of the
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IntestiPhage use in children from 1976 to 1982. Out of 580 children,
452 children were treated with the IntestiPhage preparation, 100
children were treated with antibiotics and 28 children were treated
with a combination of antibiotics and the IntestiPhage preparation. The
group treated with antibiotics exhibited clinical improvement after an
average of 29 days. The group treated with the phage-antibiotic com-
bination showed clinical improvement after 15 days, and the group that
was treated with the IntestiPhage preparation alone recovered after
only 9 days on average (Kutateladze and Adamia, 2008).
Studies performed in animals revealed strong activity of bacter-
iophages against enteropathogens. Speciﬁc phages used to combat
diarrhea caused by enteropathogenic E. coli in calves, piglets and lambs
were very eﬀective in combating diarrhea. Calves treated with phages
continued to excrete the phages in the stool as long as E. coli was de-
tected in the feces (Smith and Huggins, 1983), which demonstrates that
a positive therapeutic eﬀect was related to phage ability to propagate
within the gastrointestinal tract.
In 2011, in Germany, a large outbreak of hemolytic uremic syn-
drome and bloody diarrhea caused by Shiga-toxin producing E. coli
O104:H4 was reported. The bacteria were resistant to all penicillins and
cephalosporins, making treatment very diﬃcult. Bacteriophages were
demonstrated to be eﬀective in combating this bacterium, thus oﬀering
an alternative for combating infections caused by this antibiotic-re-
sistant pathogen (Merabishvili et al., 2012; Muniesa et al., 2012).
Sarker et al. (2012) tested the eﬃcacy and safety of bacteriophage
cocktails in a randomized, double-blind and placebo-controlled trial. A
9-phage cocktail (nine independent isolates of T4-like E. coli phages,
including four phages closely related to the T4D reference phage) was
given to 15 healthy adults from Bangladesh. Two doses were used in the
subjects: 3.0× 107 PFU per person and 3.0×109 PFU per person. The
doses were diluted in mineral water (150mL) and administered 3 times
per day (50mL). The placebo group was treated only with mineral
water. No treated volunteers showed any clinical adverse eﬀects as
evaluated by self-reports, clinical examination, or laboratory tests for
liver and kidney functions or for hematology (Sarker et al., 2012).
Another major cause of food poisoning, including gastroenteritis, is
Campylobacter jejuni, which infects at least 2 million people each year in
the United States (Siringan et al., 2011). The consumption of under-
cooked or contaminated meat or poultry appears to be the main source
of contamination by this microorganism (Wagenaar et al., 2013). One
important factor in the pathogenicity of C. jejuni is its ability to form
bioﬁlms, which makes antibiotics even less eﬀective (Ica et al., 2012; Lu
et al., 2012) and makes the eradication of C. jejuni infections particu-
larly diﬃcult. Therefore, bacteriophage therapy may be an important
alternative. This possibility prompted Siringan et al. (2011) to test the
eﬀect of two phages (CP8 and CP30) on bioﬁlms formed on a glass
surface by C. jejuni strains NCTC 11168 and PT14. Phages reduced the
number of viable bacteria from 1 to 3 log10 CFU/cm2. The authors
reached the following conclusion: “The viruses within the bioﬁlm could
not only eﬀectively target and lyse campylobacters but were also able to
disperse the extracellular matrix forming the bioﬁlm” (Siringan et al.,
2011).
A speciﬁc challenge in phage therapy against gastrointestinal in-
fections concerns the route of administration, as gastric acidity can
destroy phages. Polymer microencapsulation has proven to be very
eﬀective for the oral administration of these phages (Stanford et al.,
2010). Another treatment option for dysbiotic disorders of the human
gut involves the association of bacteriophages with probiotics. In 1981,
Tolkacheva et al. evaluated this association in leukemic patients with
dysentery. The researchers evaluated 59 patients with this condition,
using four diﬀerent treatments. The ﬁrst group received oral phage
therapy (E. coli-Proteus phage or Pseudomonas phage). The second group
was treated with a probiotic (biﬁdobacteria). The third experimental
group received a combination of bacteriophages and biﬁdobacteria. The
fourth and last group received antibiotics as conventional oral treat-
ment. The best clinical results were observed in the group that received
the combined therapy that included both bacteriophages and probiotics
(Alisky et al., 1998). Due to their bacteriolytic action, bacteriophages
have also been widely used against enterobacteria, in food production,
in animal husbandry, in product processing and in food preservation
(Endersen et al., 2014; Gutierrez et al., 2016; Sillankorva et al., 2012;
Zaczek et al., 2015). Although consuming foods treated with viruses
remains controversial for consumers, there are no reports that these
foods have caused any harmful eﬀect on any individual who consumed
the treated food (Mahony et al., 2011).
3.4. Dermal and transdermal delivery of bacteriophages
Wounds and burns cause breaches in the natural protective skin
barrier, making it susceptible to infection. Topical solutions (e.g. oint-
ments, creams, lotions) containing strictly lytic bacteriophage particles
could be used in cosmetic and pharmaceutical formulations to treat skin
infections. For purulent chronic wounds, bacteriophage particles may
be applied directly in the wound, either via injection into (or around)
the wound, via soaked bandages, or via impregnation into biodegrad-
able polymeric hydrogels with controlled-release characteristics
(Oliveira et al., 2015). Pseudomonas aeruginosa is a frequent etiological
agent in wound infections, and the emergence of multiple antibiotic
resistant strains has created signiﬁcant problems in the treatment of
infected wounds (Krylov et al., 2013). The ﬁrst clinical trial in the
world for the eﬀectiveness of phage therapy in burn wounds infected
with P. aeruginosa is about to be completed by Pherecydes Pharma in
France, Belgium and Switzerland (http://www.phagoburn.eu/). Safety
of Pseudomonas phage use in patients with leg ulcers was demonstrated
by the group of Sulakvelidze (Rhoads et al., 2009). Active phage pro-
liferation and successful bacterial kill (Mendes et al., 2013; Basu et al.,
2015) as well as markedly increased animal survival resulting from
phage treatment (Holguín et al., 2015) were demonstrated in rodents.
Skin infections can also be caused by Mycobacterium marinum,
Mycobacterium szulgai, or Treponema pertenue (Oliveira et al., 2015). A
major challenge in the treatment of skin infections caused by these
intracellular bacteria consists in developing appropriate strategies for
the targeted delivery of bacteriophage particles into mammalian cells
(Oliveira et al., 2015; Chacko et al., 2012). Since several intracellular
pathogens do have a transient extracellular living form, they can be
tackled by bacteriophages at that stage; one example is the myco-
bacteriophage D29 eﬃcient in therapy against M. ulcerans (Oliveira
et al., 2015; Trigo et al., 2013). Pseudomonas aeruginosa is a frequent
participant in wound infections, and the emergence of multiple anti-
biotic resistant strains has created signiﬁcant problems in the treatment
of infected wounds (Krylov et al., 2013).
Parenteral delivery is commonly considered the most eﬃcient
method of administration of bacteriophages. However, the parenteral
administrations, which are in fact injections, have numerous draw-
backs, such as the requirement of a health professional assistance and
increased possibility of cross-contamination (Ryan et al., 2012).
Transdermal delivery oﬀers a potential means of overcoming many of
the problems associated with systemic delivery of bacteriophages (Ryan
et al., 2012). However, typical bacteriophage particles (e.g. Caudovir-
ales), being hydrophilic viruses that diﬀer greatly from small relatively
lipophilic drug molecules, do not satisfy the criteria for eﬃcient
transdermal absorption. Two early reports of Keller (1958) and Bennett
and Foster (1966) revealed that in animal models phage penetration
through the skin was possible but not fully eﬃcient, i.e. an active phage
was noted in tissues of only some of the animals. To date, transdermal
delivery of bacteriophages has not been widely considered, except for
the novel microneedle technologies developed by Ryan et al. (2012). In
their paper, they reported for the ﬁrst time the design and evaluation of
a novel hollow polymeric microneedle device for the transdermal de-
livery of bacteriophage particles. Such a hollow microneedle device
successfully delivered viable T4 bacteriophages transdermally both in
vitro and in vivo. The microneedle-mediated transdermal delivery
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punctures the skin and bypasses the stratum corneum to create tran-
sient aqueous transport pathways of micron dimensions which, in turn,
enhances transdermal permeability. The study demonstrated that this
method allows for successful systemic phage absorption (Ryan et al.,
2012).
3.5. Tooth decay biocontrol
The oral cavity is one of the largest ecosystems in the human body,
with approximately 6 billion inhabiting bacteria and at least 35 times
more viruses. Parasitic relationships between bacteria and bacter-
iophages can occur in two ways: through bacteriolytic behavior, by
which viruses infect bacteria and kill them quickly to release their
oﬀspring, and through commensal lysogenic behavior, by which viruses
integrate into the genome of the host and participate in the genetic
functions of these bacteria (Edlund et al., 2015) (see also Section
1.1.3.). Because of this dual behavior, bacteriophages play a role in the
control of bacterial communities, aﬀecting the balance between health
and disease in the oral cavity (Canchaya et al., 2003). Through adhe-
sion and bioﬁlm formation, bacteria in the oral cavity can colonize
various oral surfaces, such as the gingival epithelium, the teeth and the
oral mucosa, leading to pathological processes, such as caries, period-
ontal disease and endodontic (dental pulp) infections (Shlezinger et al.,
2017). Bioﬁlms are formed via the adhesion of bacteria to surface ad-
hesins, increasing the force of adhesion to the surface via irreversible
binding. After adhesion, larger colonies form and become interlaced in
a polymer matrix of peptidoglycan, allowing the bioﬁlm to achieve
maturation (Salli and Ouwehand, 2015). Under the protection of the
mature bioﬁlm, bacteria are inaccessible to chemical agents (chlor-
hexidine and antibiotics), are able to escape from the oral immune
system, and are able to act as a reservoir of microorganisms to promote
chronic diseases (Khalifa et al., 2015). Due to the diﬃculty of reaching
aggregated bacteria in bioﬁlms and the ineﬀectiveness of antibiotic
agents against resistant bacteria, dental infections have become very
diﬃcult to treat. Thus, there is a need for alternatives to combat these
infections, and bacteriophage therapies have become an option for
combating orodental infections (Parasion et al., 2014).
3.5.1. Dental caries
Dental caries is a widespread and common bacteria-related disease
in humans worldwide. These infections result from the adhesion of
Streptococcus mutans, among other microorganisms, to the dental sur-
face, the formation of dental plaque and the subsequent erosion of the
tooth. The pathogenicity of this organism results from the presence of
sucrose in the diet, which leads to fermentation, lactic acid formation
and demineralization of the enamel, with the consequent formation of
caries (Dalmasso et al., 2015; Struzycka, 2014). Although phage
therapy is highly developed for the treatment of several infections, this
approach to treating dental caries caused by S. mutans is still very new.
A few studies have aimed to isolate speciﬁc phages able to counteract
caries caused by S. mutans with bacteriophages (Dalmasso et al., 2015;
Maal et al., 2015; Delisle et al., 2012; van der Ploeg, 2007), while the
isolation of bacteriophages or their lytic enzymes could be used to se-
lectively remove S. mutans from dental plaque and promote the ﬁght
against dental caries (van der Ploeg, 2007). In a recent study, Dalmasso
et al. (2015) isolated and characterized a phage that is speciﬁc for S.
mutans (ɸAPCM01). The phage was isolated from a saliva sample and
belonged to the Siphoviridae family with a B1 morphology. Lysogenic
potential of the phage and its ability to penetrate and degrade bioﬁlms
were also evaluated; the phage exhibited a strong lytic eﬀect against S.
mutans and weak lysogenic activity (0.03%). The activity of the bac-
teriophage against S. mutans was evaluated after 18 h of bacterial
contact with the phage at multiplicity of infection values (MOIs) ran-
ging from 2.5×10−5 to 250. The results showed at least a 2-fold re-
duction in optical density at 600 nm (OD600) between the control
culture and cultures of S. mutans grown with the bacteriophage at all of
the tested MOIs. These results showed that the phage was very eﬀective
in destroying S. mutans, even at smaller MOIs. This anti-S. mutans phage
activity was conﬁrmed by a decrease of at least 5.6 log CFU/mL be-
tween the control culture and the cultures grown with ɸAPCM01 at
MOIs lower than 2.5× 10−3. The lytic activity of the phage against the
bacteria was also evaluated in artiﬁcial saliva. The phage decreased the
OD600 by at least 1.5-fold when compared to cultures grown without
the bacteriophage. The phage activity against S. mutans attached to
bioﬁlms was evaluated after 48 h at various phage concentrations. At
phage doses near 102 PFU/well, there was a signiﬁcant reduction of the
bioﬁlm metabolic activity after 24 h and it failed to increase again after
48 h. At doses between 105 and 109 PFU/well, the bacteriophage caused
complete inhibition of the metabolic activity of the bioﬁlm. The authors
concluded that despite its narrow host range, the newly isolated S.
mutans phage exhibited promising antimicrobial properties. The isola-
tion of bacteriophages speciﬁc to S. mutans opens the possibility of
using these phages alone or in combination with prophylactic measures,
such as water ﬂuoridation, to combat dental caries, thus preventing this
major cause of human tooth loss (Dalmasso et al., 2015).
3.5.2. Endodontic infections
Endodontic disease is a bioﬁlm-mediated infection of the dental
pulp. The main objective of treatment in endodontic disease is to
eliminate the bacterial bioﬁlm from the root system and to disinfect it.
The treatment involves mechanical cleaning measures in combination
with the topical application of chemical agents, with the aim of com-
bating the infection (Jhajharia et al., 2015). Despite accessing the site
of infection and applying the chemical treatment directly at the site of
infection, treatment failure with worsening endodontic disease oc-
curred in approximately 1/3 of treated patients. These failure rates are
credited to the increasing rates of bacterial resistance to etiologic agents
and to the formation of root canal and extraradicular bioﬁlms (Waltimo
et al., 2005). The diﬃculties of treating endodontic infections have led
researchers to seek new therapeutic, either chemical or biological ap-
proaches to combat these infections; one of the investigated strategies is
phage therapy. Thus, eﬀorts have been made to isolate bacteriophages
speciﬁc for Enterococcus faecalis, which is a major cause of endodontic
infections and exhibits high levels of resistance against antimicrobial
agents that are regularly used in dentistry (Paisano et al., 2004; Stevens
et al., 2009).
Khalifa et al. (2015) investigated bacteriophages in the treatment of
root canals infected by E. faecalis (ATCC 700802). Bacteriophage was
isolated from a sewage treatment facility and it was named EFDG1. The
phage activity was tested against E. faecalis in vitro, against previously
formed bioﬁlms, and in a root canal treatment model. The results ob-
tained in the E. faecalis culture showed that at MOIs of 10−2–10−4,
limited bacterial growth occurred and it was followed by a rapid lysis.
At phage-bacteria rates greater than 10−2, the bacteriophage almost
completely prevented bacterial growth. The bacteriophage signiﬁcantly
reduced the activity and dispersed a 2-week-old 600-μm-width bioﬁlm
of E. faecalis. The bioﬁlm biomass evaluation was performed using
crystal violet and revealed a 5-fold reduction in the samples treated
with the phage within 7 days. Bioﬁlms that were not treated with the
phage were stable, and no reduction could be observed. To evaluate the
antibacterial activity of EFDG1 in root canal infections, the authors
used an ex vivo two-chamber bacterial leakage model of human teeth.
The results showed that in chambers containing teeth treated with the
phage turbidity was not observed. Thus, irrigation of obturated root
canals with EFDG1 resulted in reduced bacterial leakage from the root
apex in comparison to the control group. The authors concluded that
phage therapy may be an important ally in the ﬁght against E. faecalis in
root canal bioﬁlms for which conventional therapies have shown no
results (Khalifa et al., 2015). The same group further concluded in a
review on phage use in dental infections: “In the future, phages such as
EFDG1 and other phages of E. faecalis like phiEF24C, IME-EF1, and
EFLK1 can be used either as cocktails or as combinations with
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antibiotics to combat VRE (vancomycin-resistant enterococci) E. faecalis
in dental bioﬁlms” (Khalifa et al., 2016).
Paisano et al. (2004) in their study conducted in Brazil tested an E.
faecalis-speciﬁc bacteriophage isolated from a stream in the city of São
Paulo, Brazil. The authors inoculated ex vivo human dental roots with
suspensions of E. faecalis (ATCC 29212) and with the phage at three
rates: MOI 0.1, 1 and 10. All three were eﬀective in inhibiting bacteria
after 3 h of incubation. The teeth were also inoculated with the bacteria
six days before treatment with the bacteriophage to ensure the pene-
tration of the bacteria into the tooth tubules (Paisano et al., 2004). One,
two and three days after incubation with the phage, no viable bacteria
were found, showing that phage therapy was highly eﬀective in dental
roots and in the dental tubules. The authors concluded their work with
the following statement: “Phage therapy might be especially helpful for
the elimination of bacteria resistant to antibiotics, being a second front
in the ﬁght against multidrug resistant bacteria” (Paisano et al., 2004).
Phee et al. (2013) studied speciﬁc phage therapy (JBD4 and JBD44a)
against bioﬁlms produced by Pseudomonas aeruginosa (PA14) in pre-
pared root canals of extracted human mandibular incisors treated with
bacteriophages with potential bioﬁlm-degrading activities. The results
showed a signiﬁcant reduction in P. aeruginosa bioﬁlm biomass at 24 h
and 96 h after treatment (Phee et al., 2013).
4. Bacteriophage display
Bacteriophage particles exhibit a high level of organization and thus
can be viewed as elaborate nanomachines. Filamentous bacteriophage
particles can be easily genetically manipulated and the tremendous
attention they received by the scientiﬁc community allowed the de-
velopment of bacteriophage display techniques (Henry and Debarbieux,
2012; Onodera, 2010; Petty et al., 2007; Clark and March, 2006;
Benhar, 2001).
Bacteriophage display is now widely used in various domains in-
cluding antiviral research, design of novel therapeutics and vaccines,
cancer research, targeted delivery or nanotechnology (Huang et al.,
2012; Hyman, 2012; Ronca et al., 2012).
The use of bacteriophage particles to display exogenous (hetero-
logous) peptides or proteins has numerous applications, including epi-
tope identiﬁcation, antigen delivery, drug discovery, vaccine design,
targeting of eukaryotic cells, bioimaging and biosensing, enzyme dis-
play or design of nanomaterials (Henry and Debarbieux, 2012).
Bacteriophage display has been the subject of several scientiﬁc re-
views published in specialty journals (Benhar, 2001; Onodera, 2010),
and involves the engineering of bacteriophage particles so that they
become surface-decorated with exogenous (heterologous) peptides or
proteins: (i) viamolecular manipulation resulting in translational fusion
with a surface protein, (ii) via conjugation techniques, or (iii) via
competitive incorporation of foreign phage protein fusions into the
capsid, while the fusions are produced by an engineered bacterial host
of the phage (Henry and Debarbieux, 2012; Pande et al., 2010; Clark
and March, 2006; Benhar, 2001; Sidhu et al., 2000; Ceglarek et al.,
2013; Majewska et al., 2015; Hodyra and Dąbrowska, 2015).
In the ﬁrst and the most common approach, the genetic fragment
that encodes the envisaged polypeptide is fused with bacteriophage
coat protein genes, and the desired protein is presented on the surface
of the bacteriophage particle (Haq et al., 2012; Onodera, 2010; Petty
et al., 2007). This results in novel bacteriophage particles with a wide
range of potential uses.
Molecular manipulation or chemical modiﬁcation of the bacter-
iophage genome is now widespread and has been implemented for
display using major bacteriophage systems, viz. T4, T7, M13, λ, and
others (Adhya et al., 2014; Haq et al., 2012; Henry and Debarbieux,
2012; Teesalu et al., 2012; Beghetto and Gargano, 2011; Meng et al.,
2011; Rakonjac et al., 2011; Hemminga et al., 2010; Onodera, 2010;
Petty et al., 2007; Clark and March, 2006). In the molecular manip-
ulation of bacteriophages, the exogenous gene is spliced into the
bacteriophage genome as a fusion to a phage gene coding for a struc-
tural protein. This foreign gene codes for a foreign peptide that is
eventually presented on the bacteriophage surface as a fusion to a
structural protein. As a result, the bacteriophage particle becomes
surface-decorated with the product of the expression of the foreign
gene. Bacteriophage display is widely used due to its potential to carry
out large scale screening, since the spliced genetic information may be
randomly generated to produce a library, to achieve targeted delivery
or to study molecule interactions (Henry and Debarbieux, 2012).
Within the framework of libraries, the bacteriophage display technique
allows one to screen a wide array of molecules based on their speciﬁcity
or binding aﬃnity to various compounds, allowing selection of ligands
to virtually any target (Haq et al., 2012). The application of the bac-
teriophage display technique involves, in the ﬁrst step, immobilization
of the antigen moiety of interest on a surface that is then exposed to the
engineered bacteriophage library. Those bacteriophage particles pre-
senting molecules with aﬃnity to the immobilized antigen moiety will
therefore bind, while the rest of the library will be washed away. The
bound bacteriophage fraction can then be eluted and ampliﬁed, re-
sulting in a concentrated mixture of bacteriophage particles presenting
the relevant molecule. Repetition of this procedure, in a process called
“biopanning” (or aﬃnity selection), allows identiﬁcation of molecules
exhibiting a high binding aﬃnity to the antigen moiety of interest
(Vodnik et al., 2011; Benhar, 2001). Both the size and charge of the
peptide displayed on the surface of the bacteriophage particle must be
taken into account, since they inﬂuence the number of peptide moieties
that can be displayed on the surface of a bacteriophage particle. In
order to maintain good bacteriophage production during propagation,
the normal processing of the bacteriophage capsid proteins should not
be hindered by the fused peptide moiety so as to allow for the correct
expression of the capsid proteins and to let them fulﬁll their biological
roles in the bacteriophage replication process (Henry and Debarbieux,
2012; Imai et al., 2008).
The second approach to engineering bacteriophage particles for the
display of foreign elements is chemical modiﬁcation, in a process
termed bioconjugation (Patel and Swartz, 2011). In this biotechnolo-
gical approach, attachment of speciﬁc molecules onto the surface of the
bacteriophage particle allows decoration of both the outside and the
inside of the capsid protein shell, allowing the use of the viral particles
as carriers (Kovacs et al., 2007).
This approach allows for presentation of foreign elements on a
phage surface without genetic modiﬁcations of the phage. This means
that bioconjugation helps to escape the necessity to construct geneti-
cally modiﬁed organisms (GMOs). From the practical point of view, this
can be an important advantage for phage-derived products developed
this way.
The third alternative for phage display is “competitive phage dis-
play”. This method allows for presentation of foreign peptides or pro-
teins on the phage surface without any modiﬁcations in the phage
genome, since protein fusions are expressed by an engineered bacterial
host, e.g. from expression vectors. In the same bacterial cell, when in-
fected by a target phage, wild types phage proteins are also produced.
Wild type and fusion proteins are randomly (competitively) in-
corporated into the phage capsid. This is again a method that allows
one to avoid the necessity of GMO construction, but it also oﬀers more
speciﬁc control of the capsid site that is decorated with a foreign ele-
ment. This is because these elements are fused only to selected, pre-
deﬁned phage surface proteins, like in the classic phage display
(Ceglarek et al., 2013; Majewska et al., 2015).
5. Vaccine carriers
Two distinct approaches have been developed so far for antigen
delivery with phage vaccines, termed “phage display vaccines” and
“phage DNA vaccines” (Rodríguez-Rubio et al., 2016; Adhya et al.,
2014; Clark and March, 2004). Phage display vaccines aim at producing
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immunogenic bacteriophage particles. Their surfaces are decorated
with foreign antigens, which is achieved by expression of antigens as
fusion products of one of the selected structural proteins of the bac-
teriophage virion (Majewska et al., 2015). Bacteriophage DNA vac-
cines, in turn, are produced by incorporating foreign antigen genes in
the bacteriophage genome under control of strong eukaryotic pro-
moters (Adhya et al., 2014; Golkar et al., 2014; Haq et al., 2012; Clark
and March, 2004, 2006). In bacteriophage DNA vaccines, the bacter-
iophage particle acts as a passive carrier to transfer the foreign DNA
into mammalian cells where the antigen gene is then expressed. These
two approaches are often combined to produce bacteriophage particles
that carry a foreign antigen gene and that display a protein or peptide
on their surface. Hence, bacteriophages have the potential to be used as
vaccine carriers via two distinct ways, viz. (i) by direct vaccination with
bacteriophage particles carrying vaccine antigens decorating their
surface, or (ii) by using the bacteriophage particles to deliver a DNA
vaccine which is an expression cassette incorporated into the bacter-
iophage genome (Adhya et al., 2014; Golkar et al., 2014; Haq et al.,
2012; Clark and March, 2004, 2006). In phage display-based vaccina-
tion, bacteriophage particles may be engineered to display a speciﬁc
antigenic peptide or protein on their surface or, alternatively, bacter-
iophage particles displaying peptide libraries may be screened with a
speciﬁc antiserum aiming at isolating protective antigens or mimo-
topes, i.e. peptides mimicking both the secondary structure and the
antigenic properties of a protective carbohydrate, protein or lipid
moiety, despite possessing a diﬀerent primary structure (Clark and
March, 2006). In a handful of cases, however, whole bacteriophage
particles displaying antigenic proteins have been used as vaccines in
animal models (Wang and Yu, 2004; Irving et al., 2001).
Instead of producing a transcriptional fusion to a capsid coat pro-
tein, antigenic molecules can also be artiﬁcially conjugated at the sur-
face of bacteriophage particles after propagation, further increasing the
range of antigens that can be displayed (Haq et al., 2012; Clark and
March, 2006). Since bacteriophage particles contain potential ad-
juvants like phage proteins and DNA (Haq et al., 2012; Clark and
March, 2004, 2006; Dąbrowska et al., 2014), a speciﬁc antigen present
on the bacteriophage capsid would not need separate protein pur-
iﬁcation and subsequent conjugation to a carrier molecule before im-
munization. However, it has been shown more recently that unmodiﬁed
bacteriophage particles may be used to deliver DNA vaccines more ef-
ﬁciently than standard plasmid DNA (Haq et al., 2012; Clark and
March, 2006), with the vaccine gene (under control of a eukaryotic
expression cassette) being cloned into a standard lambda bacteriophage
particle and concomitant injection of puriﬁed (whole) bacteriophage
particles into the host (Haq et al., 2012). The bacteriophage capsid
protects the DNA from degradation and at the same time it targets the
vaccine to the antigen-presenting cells. According to Clark and March
(2006), there is also a possibility for producing a “hybrid bacteriophage
vaccine”, where a eukaryotic promoter-driven DNA vaccine is in-
tegrated within the bacteriophage particle and a bacteriophage display
variant of the same antigen is integrated on the bacteriophage particle's
surface, aiming at eﬃciently targeting both the humoral and cellular
arms of the immune system (Adhya et al., 2014; Clark and March,
2006). Additionally, it might also be possible to modify the surface of a
bacteriophage particle-based vaccine with speciﬁc protein or peptide
sequences aiming at the preferential targeting of the particle to parti-
cular immune cell types. Phage display has been used mostly for the
identiﬁcation of immunogenic epitopes or mimotopes on displayed
peptides which, in turn, could become lead molecules for the design of
peptide-based vaccines (Rodríguez-Rubio et al., 2016; Adhya et al.,
2014; Haq et al., 2012; Benhar, 2001).
6. Gene delivery
The DNA packaging systems of bacteriophages have been identiﬁed
as a special type of nano-vehicle for gene delivery (Karimi et al., 2016;
Haq et al., 2012; Clark and March, 2006). While the DNA packaging
motor of bacteriophage Phi29 was shown to be an eﬃcient machine for
packaging viral ds-DNA, its RNA had a high tendency to form dimers,
trimers and hexamers (Lee et al., 2009). This motor that uses ATP to
push DNA into the procapsid requires only three components, the gp10
(connector) and gp16 proteins and a small packaging RNA (pRNA)
(Henry and Debarbieux, 2012). By engineering this molecular ma-
chinery of bacteriophage Phi29 RNA, Hao et al. (2014) produced a
nanocage. In particular, the special anisotropic shape of bacteriophage
M13 (Karimi et al., 2016) together with its long rod-like architecture
displays liquid-crystal-like properties. Due to the high aspect ratio of
this bacteriophage particle, its penetration into the targeted cells is
improved due to a higher number of ligand-receptor interactions. In
contrast to spherical-shaped bacteriophages, their ﬁlamentous coun-
terparts have a tendency to migrate toward the blood vessel walls when
administered in vivo, and therefore have a better chance to interact with
their receptors (Karimi et al., 2016; Bakhshinejad et al., 2015). Bac-
teriophage particles can thus be used as designed nanocarriers (Karimi
et al., 2016; Henry and Debarbieux, 2012) for the targeted delivery of
both therapeutic agents and genetic sequences, representing a new tool
of nanotechnology in drug delivery systems. The phage coat protects
the DNA from degradation after injection, and the ability to display
foreign molecules on the phage coat also enables targeting of speciﬁc
cell types (Clark and March, 2006). Surface decoration of the bacter-
iophage particle with targeted ligands provides versatility and high
speciﬁcity in this regard.
7. Food biopreservation and safety
Temperate bacteriophages (i.e., lysogenic) are generally considered
unsuitable for the development of biocontrol strategies. However, their
virulent counterparts (i.e., strictly lytic viruses) are very much appro-
priate for biocontrol (downstream) applications. Biocontrol of patho-
gens in food products may in fact represent an economically viable ﬁeld
for bacteriophage-based biocontrol (Henry and Debarbieux, 2012).
Several systems have already been approved by authorities for use on
food products, viz. ListShield (from Intralytix) or LISTEX (from Micreos
Food Safety) for the control of Listeria monocytogenes, EcoShield (from
Intralytix) for targeting Escherichia coli O157:H7 and SALMONELEX
(from Micreos Food Safety) for the control of Salmonella (Rodríguez-
Rubio et al., 2016; Henry and Debarbieux, 2012). Bacteriophages were
also found to be eﬃcient for the decontamination of livestock raised for
the food industry, therefore limiting the risk of pathogens reaching the
food chain. They were also used to detect pathogens in animal-derived
alimentary products (Henry and Debarbieux, 2012). Phage-mediated
biocontrol has successfully been applied against many pathogens that
cause economic losses in food production (see Table 2).
Phages infect bacteria that cause important losses in all of these
areas of food and agriculture. Studies of their biology and bio-
technology, as well as of useful phage gene products (e.g. endolysins),
have the potential to improve food safety and agricultural yields. There
are several useful reviews summarizing current as well as envisaged
applications of bacteriophages in the entire food chain. They also ad-
dress the concerns of consumers about chemical preservatives due to
both safety and toxicity (Jhamb, 2014; Haq et al., 2012; Sillankorva
et al., 2012). Additionally, outbreaks of food-borne infections asso-
ciated with the increasing prevalence of antibiotic-resistant micro-
organisms has led to a search for novel food (bio)preservation techni-
ques. Pre- and postharvest bacteriophage research has targeted many
life-threatening bacteria including Escherichia coli O157:H7 as thor-
oughly discussed by Sillankorva et al. (2012) (see Table 2).
Shigella is one of the most important waterborne and foodborne
bacterial pathogens in the world, usually related to the ingestion of
contaminated water and food. Recently, Jun et al. (2016) reported on
the potential of a virulent Myoviridae bacteriophage (pSs-1) isolated
from environmental water in South Korea as a biocontrol agent that can
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be used to control contaminated waters with Shigella ﬂexneri and Shi-
gella sonnei (Jun et al., 2016). Three major conclusions arise from the
literature survey: (i) bacteriophage therapy in animals is able to reduce
levels of foodborne pathogen and control the pathogen load upon entry
at the slaughterhouses; (ii) the bacteriophage-based biocontrol of pa-
thogens in foods signiﬁcantly reduces dangerous pathogens and appears
to be a promising alternative to traditional food preservation techni-
ques; (iii) bacteriophages used in agricultural settings are at least as
eﬃcient as the agents conventionally used to control the growth of
plant-related bacterial pathogens.
The company Omnilytics (www.omnilytics.com) developed the
bacteriophage product Agriphage for the control of bacterial spot
caused by Xanthomonas campestris or bacterial speck caused by
Pseudomonas syringae. The eﬀectiveness of this product in protecting
crops against these pathogens is reﬂected by the report of a marked
increase in yield. The control of pathogens of fruits and vegetables is
highly important, since these foods cannot be further processed to kill
any pathogens present without the risk of imparting damage.
8. Bacterial biosensing devices
Rupture of the host bacterial cell induced “from within” is the last
step in the bacteriophage lytic replication cycle, being mediated mainly
by two special proteins produced in the last stage of the virion progeny
assemble, viz. holins (which perforate the inner side of the cytoplasmic
membrane) and endolysins (which pass through the newly formed
pores and access the peptidoglycan layer, degrading it and resulting in
destabilization of the murein sacculus). In addition to the liberation of
the virion progeny particles, lysis of the host bacterial cell also results in
the release of intracellular components, some of which may be
exploited as markers for biodetection purposes (Ahmed et al., 2014;
Zourob and Ripp, 2010). Bacterial cytoplasmic markers utilized in
bacteriophage-mediated bacterial detection include (but are not limited
to) detection of released ATP, adenylate kinase, bacterial β-D-galacto-
sidase, and α- and β-glucosidase (Schmelcher and Loessner, 2014;
Zourob and Ripp, 2010).
Bacteriophage particles are also suitable tools for speciﬁc impedi-
metric detection of bacteria, since addition of bacteriophage particles to
a sample results in retardation of changes in impedance if the target
organism is present. This is due to changes in conductivity of the
growth medium that are caused by the growth of microorganisms,
mostly through transformation of large uncharged metabolites (e.g.
carbohydrates) to smaller charged molecules (e.g. acids) (Schmelcher
and Loessner, 2014; Zourob and Ripp, 2010). Zourob and Ripp (2010)
provided an extensive overview of the techniques, methodologies and
assays that employ bacteriophage particles in biosensing applications.
Further, bacteriophage particles recognize speciﬁc molecular motifs
expressed on the bacterium surface, to which they bind and inject their
genetic material (Ahmed et al., 2014; Sorokulova et al., 2014; Gervais
et al., 2007; Clark and March, 2006). The high speciﬁcity of this re-
cognition constitutes a remarkable tool to provide a rapid biodetection
result (≤1 day). This is of utmost importance when an emergency de-
tection is needed, e.g. in an outbreak situation (Sorokulova et al., 2014;
Henry and Debarbieux, 2012). Additionally, in the context of hospitals,
health care centers (Ahmed et al., 2014; Sorokulova et al., 2014;
Smietana et al., 2011) and food industries (Singh et al., 2013), the rapid
identiﬁcation of the presence of bacterial pathogens is vital in order to
prevent the spread of infections by implementing appropriate control
strategies (Henry and Debarbieux, 2012; Smartt et al., 2012). Common
methods for detection and identiﬁcation of pathogens in food products
(Schmelcher and Loessner, 2014; Singh et al., 2013), drinking water
supplies and hospitals continue to rely mostly on conventional micro-
biological culture techniques (Gervais et al., 2007). However, only a
few diagnostic kits for pathogen detection in human samples (e.g.
FastPlaqueTB (BIOTEC Laboratories Ltd, Mycobacterium tuberculosis)
assay, KeyPath (MicroPhage Inc., Staphylococcus aureus MRSA/MSSA)
test, xTAG Gastrointestinal Pathogen Panel (GPP) (Luminex Molecular
Diagnostics Inc., S. typhimurium, and MRSA/MSSA Blood Culture Test)
have reached the market so far (Schmelcher and Loessner, 2014;
Sorokulova et al., 2014; Henry and Debarbieux, 2012; Zourob and Ripp,
2010). The constantly increasing number of disease-causing bacteria
that are resistant to one or more anti-bacterial drugs utilized for therapy
is the driving force for the development of early and speedy biodetec-
tion systems for these pathogens. Traditional pathogen detection tech-
niques include microbiological and biochemical assays that are both
time-consuming and labor-intensive, whereas antibody or DNA-based
techniques require substantial sample preparation and puriﬁcation. On
the other hand, biosensing devices based on bacteriophage particles
have demonstrated over the last few years a remarkable potential to
surpass the aforementioned restrictions, oﬀering rapid, eﬃcient and
highly sensitive biodetection techniques for (antibiotic-resistant) bac-
teria (Ahmed et al., 2014).
Currently, the applications of bacteriophage particles in the detec-
tion of pathogens can be divided into two categories: (i) those based on
inert bacteriophage particles or isolated bacteriophage proteins, and (ii)
those that require a non-going infectious cycle (Schmelcher and
Loessner, 2014; Henry and Debarbieux, 2012). One may simply use the
lytic nature of the bacteriophage as the “sensor” to detect the presence
of its bacterial host. This is the principle of the FASTPlaqueTB assay for
the detection of Mycobacterium tuberculosis in sputum, in which bac-
teriophages infecting the slow-growing Bacillus tuberculosis are subse-
quently detected when forming plaques on a fast-growing strain
(Webster, 2010; Rees and Loessner, 2005). Balcão et al. (2013, 2014b)
reported on the development of carbohydrate hydrogels for the stabi-
lization of bacteriophage particles aiming at bacterial biosensing, and
thoroughly studied the diﬀusion of bacterial cells from the surface of
the hydrogel into its core. Besides using native, unaltered phage par-
ticles for bacterial detection, molecular cloning techniques make it
possible to engineer bacteriophage particles to carry a speciﬁc reporter
gene (Sorokulova et al., 2014; Zourob and Ripp, 2010; Ripp et al.,
2006). Upon infection of a target host cell, the gene is expressed and
allows detection of its product, e.g., by measuring bioluminescence,
ﬂuorescence, or enzymatic conversion of a chromogenic substrate
(Schmelcher and Loessner, 2014; Ripp et al., 2006). Bacteriophage
particles carrying a luciferase gene for bacterial detection account for
the predominant uses (Schmelcher and Loessner, 2014; Zourob and
Table 2
Phage-mediated biocontrol of pathogens that cause economical loss in food
production.
Modiﬁed from Haq et al. (2012), Sillankorva et al. (2012), Adriaenssens et al.
(2012) and Fujiwara et al. (2011).
Pathogen Loss in food production
Aeromonas spp ﬁsh in aquaculture
Paenibacillus larvae honeybee
Xanthomonas pruni peaches, cabbage and peppers
Xanthomonas
campestris
tomatoes
Pseudomonas tolaasii mushrooms
Salmonella poultry products, pork, processed foods (ripened
cheese), fresh-cut melon and apple, frankfurters, raw
and cooked beef, fresh tomatoes, mung bean sprouts
and alfafa seeds, and chocolate milk
Campylobacter poultry products and beef
Listeria monocytogenes beef, fresh melons and apples, honeydew melon, red-
smear soft cheese, cooked ham, salmon ﬁllet, catﬁsh
ﬁllets, and chicken
Escherichia coli
O157:H7
poultry (broiler chicken), lamb, sheep, cattle and steer
meat, tomato, spinach, lettuce and cantaloupe
Staphylococcus aureus dairy cattle, raw milk whey, milk curd, pasteurized
milk, and cheese
Dickeya solani potato
Ralstonia solanacearum Potato, tomato, aubergine (egg plant), banana, ginger,
tobacco, sweet pepper, olive, soybean
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Ripp, 2010; Ripp et al., 2006), with major advantages of using luci-
ferase genes as reporters being the highly sensitive detection of the
bioluminescent signal they generate. Additionally, several other re-
porter genes have been used to construct reporter bacteriophage par-
ticles, of which genes encoding ﬂuorescent proteins such as green
ﬂuorescent protein (GFP) (Vinay et al., 2015; Lee et al., 2013; Zourob
and Ripp, 2010) have been found to be particularly suitable. GFP
combines many desirable properties such as high stability, low toxicity,
and the fact that ﬂuorescence is triggered by excitation light (Vinay
et al., 2015), abolishing the requirement for adding a substrate as re-
quired for luciferases (Schmelcher and Loessner, 2014).
Methods that have been used over the last two decades to detect
pathogenic bacteria include (but are not limited to) using bacter-
iophage particles speciﬁcally to deliver reporter genes (e.g. lux
(Schmelcher and Loessner, 2014; Petty et al., 2007; Kodikara et al.,
1991) or green ﬂuorescent protein (Schmelcher and Loessner, 2014;
Funatsu et al., 2002)) that are expressed after infection of the target
bacterial host, using bacteriophage particles with a ﬂuorescent dye
covalently attached to their protein capsids and detecting speciﬁc ad-
sorption (Goodridge et al., 1999), the detection of released cellular
intracytoplasmic components (e.g. adenylate kinase) (Corbitt et al.,
2000) after speciﬁc bacteriophage-mediated lysis, and using bacter-
iophage particles displaying peptides or antibody fragments that spe-
ciﬁcally bind bacterial pathogens or toxins (Petrenko and Vodyanoy,
2003).
The chemical attachment of genetically biotinylated T4 bacter-
iophage particles (engineered to express a biotin-binding domain on a
capsid protein using a bacteriophage display technique) onto strepta-
vidin-coated (derivatized) gold surfaces (Gervais et al., 2007) or
streptavidin-coated magnetic beads and microcrystalline cellulose
beads (Lee et al., 2013; Tolba et al., 2010) has also been reported.
Chemical attachment of bacteriophage particles onto (bio)sensor sur-
faces could signiﬁcantly improve both the stability and performance of
the overall biodetection platform. The chemical biotinylation of bac-
teriophage particles has already been shown to increase the eﬃciency
of bacteriophage-based biosorbents when compared to simple physical
adsorption (Lee et al., 2013; Zourob and Ripp, 2010; Sun et al., 2001).
Such genetic biotinylation opens the possibility of leveraging the aﬃ-
nity of the streptavidin/biotin system for the attachment of the bac-
teriophage particles onto surfaces (Petty et al., 2007). Additionally, as
opposed to bacteriophage particles biotinylated via chemical proce-
dures, the biotin is in these cases exclusively present on the bacter-
iophage capsid and not on its tail, potentially allowing the oriented
attachment of the bacteriophage particle onto surfaces (Sorokulova
et al., 2014; Webster, 2010; Gervais et al., 2007; Sun et al., 2001).
Bacteriophage particles bound from their head capsid protein onto the
(bio)sensor surface would also allow the tail ﬁbers to face the medium,
enabling more eﬃcient capture of their host bacterium (Tolba et al.,
2010; Gervais et al., 2007). The oriented immobilization of bacter-
iophage particles onto speciﬁc surfaces results in highly active biosor-
bents that can simultaneously capture and detect a target bacterium
with high sensitivity (Tolba et al., 2010). Hence, bacteriophage parti-
cles represent potential tools for (bio)diagnostic assays due not only to
their very high speciﬁcity for bacterium hosts, but also to their signal-
amplifying properties (Lee et al., 2013). Every single phase of the
bacteriophage lytic replication cycle, from the initial recognition of its
speciﬁc host cell to the ﬁnal cell lysis events, may be harnessed in
diﬀerent ways for the purpose of bacterial detection (Sorokulova et al.,
2014; Lee et al., 2013). In addition to intact bacteriophage particles,
bacteriophage-derived aﬃnity molecules such as cell wall binding do-
mains (CBDs) and receptor binding proteins may serve for this purpose
(Rodríguez-Rubio et al., 2016; Schmelcher and Loessner, 2014).
Generally speaking, a biosensing device integrates several compo-
nents, including a solid surface to which the recognition elements are
attached; a transduction element that can be electrochemical (e.g. im-
pedimetric), optical (e.g based on surface plasmon resonance) or mass-
based (e.g. magnetoelastic); a signal ampliﬁer; a signal detector; and a
signal display (Schmelcher and Loessner, 2014; Sorokulova et al., 2014;
Hiremath, 2013; Singh et al., 2013; Webster, 2010; Zourob and Ripp,
2010). All these biosensing components were described in detail else-
where (Zourob and Ripp, 2010). Vital for the performance of a bac-
teriophage-based biosensor is the eﬀective immobilization of the bac-
teriophage particles or bacteriophage-derived recognition elements on
the biosensor solid surface (Webster, 2010; Zourob and Ripp, 2010).
Therefore, strategies used for immobilization of those entities include
physical absorption, covalent (undirected) immobilization via chemical
functionalization, and oriented immobilization via genetic modiﬁcation
of the recognition element (Hosseinidoust et al., 2014; Sorokulova
et al., 2014; Singh et al., 2012; Webster, 2010). Regretfully, bacter-
iophage immobilization via physical absorption is often hampered by
the weak binding produced and inconsistent density of recognition
elements attached to the biosensor surface, but this may be overcome
by chemical coupling (Webster, 2010; Singh et al., 2009). Self-as-
sembled monolayers encompassing chemisorbed elements play an im-
portant role in immobilizing bacteriophage particles. Several re-
searchers have reported that modiﬁcation of solid surfaces with
cysteine followed by treatment with 2% (v/v) glutaraldehyde, resulted
in a 37-fold enhancement of bacteriophage particle attachment com-
pared with plain physical adsorption (Sorokulova et al., 2014; Singh
et al., 2009). The strategy of oriented bacteriophage immobilization
oﬀers an additional advantage since the binding sites/domains are ex-
posed and therefore available for capturing target cells (Schmelcher and
Loessner, 2014). Bacteriophage particles integrate several properties
that are highly desirable in designing biodetection systems for bacterial
pathogens (Zourob and Ripp, 2010): (i) bacteriophage particles are
highly speciﬁc for their target host cells; (ii) bacteriophages can dis-
criminate between viable and non-viable bacterial host cells; (iii) bac-
teriophage particles function under a wide array of environmental
conditions (some of them harsh); (iv) strictly lytic bacteriophages act as
signal ampliﬁers; and (v) bacteriophage particles are inexpensive and
easy to isolate and propagate (Singh et al., 2013; Petty et al., 2007). In
addition, bacteriophage particles oﬀer a virtually unlimited selection of
tools (including complete bacteriophage particles and bacteriophage-
derived aﬃnity molecules such as cell-wall binding domains and re-
ceptor-binding proteins (Singh et al., 2013)) that can be harnessed for
diﬀerent biodetection strategies.
9. Bioﬁlm and bacterial growth control: surface disinfection
An important challenge in health-care and food industry environ-
ments is related to the presence of bacterial bioﬁlms on medical devices
and industry surfaces (Rodríguez-Rubio et al., 2016; Hosseinidoust
et al., 2014). It is now commonly accepted that most bacterial species
live in communities and thrive in complex biostructures called bioﬁlms.
Bioﬁlms consist of extracellular polymeric materials (i.e. the matrix)
surrounding bacterial cells, and they are directly related to serious
health problems caused by bacterial infections in diseases such as va-
ginosis, cystic ﬁbrosis, and dental plaque and in transmission of bac-
terial infections associated with medical devices. Planktonic, free-
ﬂoating bacterial cells express diﬀerent phenotypes as compared with
their counterparts inside bioﬁlm communities. The study of these dif-
ferences is of utmost importance in order to achieve a better under-
standing of why bacterial cells in bioﬁlms are usually more pathogenic
than their planktonic counterparts. Bacteria embedded in bioﬁlms are
considerably less susceptible to antibiotics and disinfectants than their
planktonic counterparts, due to both a reduced growth rate and limited
access of the antibacterials to bacterial cells in a bioﬁlm (Rodríguez-
Rubio et al., 2016; Davies, 2003). Since bacterial bioﬁlms pose con-
siderable health threats, innovative antimicrobial approaches using
bacteriophage-derived products or engineered bacteriophage particles
are being developed (Salmond and Fineran, 2015; Hosseinidoust et al.,
2014). Considerable research has therefore been focused on endolysins,
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peptidoglycan hydrolases involved in bacterial cell lysis during bac-
teriophage replication (Roach and Donovan, 2015; Salmond and
Fineran, 2015; Briers et al., 2014; Rodríguez-Rubio et al., 2013).
Endolysin-based antibacterials eﬃciently kill Gram-positive bac-
teria upon contact by speciﬁc cell wall hydrolysis. However, a major
hurdle in their exploitation as antibacterials against Gram-negative
pathogens is the impermeable lipopolysaccharide layer surrounding
their cell wall. Hence, Briers et al. (2014) developed and optimized an
approach to engineer these enzymes as outer membrane-penetrating
endolysins (coined Artilysins), rendering them highly bactericidal
against Gram-negative pathogens, including Pseudomonas aeruginosa
and Acinetobacter baumannii.
Loss of the structural integrity of the bacterial cell wall upon hy-
drolysis of the peptidoglycan layer causes lysis via osmotic imbalance.
Additionally, in Gram-negative bacteria the outer membrane must also
be breached by protein complexes (spanins) that fuse outer and inner
membranes (Salmond and Fineran, 2015). Bacteriophage endolysins
encompass a diverse range of hydrolytic enzymes. Most of them are
species-speciﬁc, while some are more promiscuous. Typically, en-
dolysins contain an enzymatically-active domain and a cell wall-
binding domain (Roach and Donovan, 2015; Salmond and Fineran,
2015). The ﬁrst commercially available endolysin, Staphefekt (Micreos
Human Health, The Netherlands), is available for the treatment of
human skin infections caused by Staphylococcus aureus.
Another enzyme-based approach makes use of bacteriophage-de-
rived tail spikes or diﬀusible polysaccharide-depolymerizing enzymes
(Salmond and Fineran, 2015). These enzymes reduce the levels of
surface polymers such as exopolysaccharides (EPS) and lipopoly-
saccharides (LPS) (Roach and Donovan, 2015; Salmond and Fineran,
2015). Instead of lysing bacterial cells, the removal of polysaccharides
may lead to disruption of the bioﬁlm matrix, reducing bacterial viru-
lence and assisting in bacterial clearance by the host immune systems
(Salmond and Fineran, 2015). Lu and Collins (2007) engineered bac-
teriophage T7 so that it could express an EPS-degrading enzyme during
infection of an Escherichia coli bioﬁlm. Bacterial cell lysis released the
EPS-degrading enzyme, facilitating further bacteriophage infections
and increasing the anti-bioﬁlm eﬀect (Lu and Collins, 2007). Hence,
problems associated with bacterial bioﬁlms could be overcome by using
endolysins and virion-associated peptidoglycan hydrolases (Rodríguez-
Rubio et al., 2016). Sass and Bierbaum (2007) and Son et al. (2010)
demonstrated that recombinant endolysins from bacteriophages phi11,
phi12 and SAP-2 were able to remove bioﬁlms of Staphylococcus aureus
formed on polystyrene surfaces, and Domenech et al. (2011) reported
that bacteriophage endolysins Cpl-1 and Cpl-7 were highly eﬀective in
removing bioﬁlms of Streptococcus pneumoniae. In the last few years,
Shen et al. (2013) reported that endolysin PlyC directly lysed Strepto-
coccus pyogenes cells within the bioﬁlm matrix due to the ability of this
endolysin to diﬀuse through the extracellular material constituting the
bacterial bioﬁlm.
10. Bacteriophage tethering
Most steps in the control of gene expression depend on bi-functional
RNA-binding proteins, since they have the ability both to bind to RNA
and to interact with other proteins in a functional complex (Keryer-
Bibens et al., 2008; Coller and Wickens, 2007). A powerful approach
developed to study in vivo the functional properties of such bi-func-
tional proteins, independently of their RNA-binding capability, is to
tether (or attach) them to speciﬁcally engineered reporter mRNAs
whose fate can be easily followed (Keryer-Bibens et al., 2008). Two
tethering systems have been mainly used in eukaryotic cells, namely the
MS2 bacteriophage capsid protein system and the lambda bacter-
iophage N-B box system (Keryer-Bibens et al., 2008; Coller and
Wickens, 2007).
Another potential use of bacteriophage tethering involves the con-
trolled covalent attachment of bioactive bacteriophage particles in
medical devices so that these become resistant to the development of
bioﬁlms (Hosseinidoust et al., 2014; Donlan et al., 2013). In the patent
application described by Donlan et al. (2013), bacteriophage particles
are tethered to the surface of an indwelling medical device or a hy-
drogel-type coating on the surface of the device by covalent binding.
Bacteriophage lytic activity is maintained in this process, thus pre-
venting bioﬁlm formation on the surface of the device when in use,
leading to increased safety.
Uyanga (2015) described two novel pathways for engineering M13
bacteriophage aiming at cancer therapy applications, by exploiting the
uniquely malleable biology of the M13 ﬁlamentous bacteriophage
(Khalil et al., 2007). By engineering ﬁlamentous bacteriophages of
shorter lengths via constructing a proprietary set of small viral ssDNA
that are packaged by M13 capsid proteins (Uyanga, 2015), the small
bacteriophage particles retained the M13 major and minor coat pro-
teins previously manipulated to serve as tethers to carry various
therapy and imaging agents and target speciﬁc cancer sites. The in-
corporation of bacteriophage particles into medical materials so as to
provide an antibacterial eﬀect upon contact of that material with the
target bacterium would be of utmost importance in health-care en-
vironments. Such biomaterials could respond to an emergent infection
in advance before clinical signs become evident, with potential to
greatly improve patient prognosis. Hence, bacteriophage-impregnated
(bio)materials could be used as medical implants and in applications
relevant to hospital hygiene. Another example could be bacteriophage-
tethered wound dressings and dermal substitutes for targeted therapy
that would allow production of infection-responsive biomaterials such
as biodegradable and biocompatible ﬁlms and highly porous cryogels,
designed for the management and repair of skin injuries, particularly
burns and ulcers, where the risk of infection is high. Bacteriophages
have high speciﬁcity toward bacteria, which makes them an attractive
natural bioreceptor. In a recent study by Tlili et al. (2013), bacter-
iophages were chemically tethered to SAM-functionalized gold elec-
trodes to quantify Escherichia coli cells.
11. Bacteriophage-based nanomaterials
A growing number of nanotechnological applications are driving
many researchers towards exploitation of bacteriophage particles (Rios
et al., 2018) as vectors or as matrices for new nanodevices, with a wide
array of applications in nanomedicine (Karimi et al., 2016; Scibilia
et al., 2016; Farr et al., 2014; Fan et al., 2012; Henry and Debarbieux,
2012; Hyman, 2012; Rakonjac et al., 2011). Filamentous, MS2, lambda
and T bacteriophage particles can be used as designed nanocarriers for
the targeted delivery of both therapeutic agents and diagnostic reporter
molecules, hence representing a new aspect of nanotechnology in drug
delivery systems (Karimi et al., 2016). The bacteriophage capsid con-
sists of several protein subunits assembled together. Although this
protein scaﬀold is already extensively used for the display (surface
decoration) of molecules, its structure can also be used as a nanocage to
entrap biomolecules of interest (Karimi et al., 2016; Lee et al., 2016a).
Each type of bacteriophage has a particular shape, a diﬀerent capacity
for loading cargo, a speciﬁc production time, and its own mechanisms
of supramolecular assembly, which have enabled them to act as tunable
carriers (Karimi et al., 2016).
In their review paper, Karimi et al. (2016) extensively tackled the
major bacteriophage species that have been used in drug and gene
delivery systems, together with biological applications of bacter-
iophages as novel targeting ligands and targeted therapeutics. Ideally, a
protein construct must deliver relevant biomolecules upon command to
a speciﬁc target while avoiding neutralization by the immune system.
With this goal in mind, modiﬁcation of the internal and external sur-
faces of the icosahedral single-stranded RNA coliphage MS2 capsid was
carried out by Kovacs et al. (2007). Their goal was to turn the capsid
into an eﬃcient (cage-encasing) drug delivery system. They performed
extensive PEGylation of bacteriophage MS2 capsids, producing a
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stealth-like eﬀect, to eﬀectively reduce neutralization by antibodies.
This was followed by binding a ligand to the distal terminations of the
PEG chains (making it possible to attach targeting moieties, to direct
the cargo to a speciﬁc target) and encaging large “drug-like” molecules.
In another (more recent) study, the synthesis of MS2 particles able to
speciﬁcally deliver a number of molecules such as nanoparticles, drugs,
siRNAs or toxins, to hepatocellular carcinoma cells was described
(Ashley et al., 2011) via the co-display of a targeting peptide and a
fusogenic peptide promoting endosomal escape.
The structural features of bacteriophages (viz. genomic and pro-
teomic information in the same body) associated with the ease of their
genetic engineering to accommodate various target genes and/or pro-
teins make them very useful in the design of novel drug delivery car-
riers (Scibilia et al., 2016; Farr et al., 2014; Merzlyak and Lee, 2006).
The use of bacteriophage particles in drug delivery has three potential
major applications: gene therapy, drug targeting and target imaging.
Since in gene therapy it is vital that a speciﬁc gene is delivered eﬃ-
ciently to a speciﬁc tissue or cell type, bacteriophage particles can be
used to achieve such speciﬁcity via engineering targeting peptide se-
quences on the surface of their capsids (Scibilia et al., 2016; Farr et al.,
2014; Merzlyak and Lee, 2006). Additionally, bacteriophage particles
are also good gene delivery vectors because they protect DNA from
degradation. Very recently, Scibilia et al. (2016) reported on the for-
mation of silver nanoparticle (AgNPs)-bacteriophage networks that can
ﬁnd application in the biomedical ﬁeld of advanced biosensing and
targeted gene and drug delivery.
Several characteristics render ﬁlamentous bacteriophages (and
especially M13 bacteriophage particles) ideal for nanotechnology ap-
plications (Bakhshinejad and Sadeghizadeh, 2014). M13 bacteriophage
virions have the ability to self-assemble into nanoscale structures,
meaning that the major part of the structural information present in the
bacteriophage capsid is carried by capsid proteins themselves and does
not require the involvement of other proteins (Bakhshinejad and
Sadeghizadeh, 2014). One of the most important applications of bac-
teriophage nanoparticles in neural regeneration is the development of
biomimetic scaﬀolds for tissue engineering purposes and, indeed, over
the last few years, M13 bacteriophage nanoparticles have received
much attention for the design and synthesis of nanomaterial scaﬀolds
for neural tissue engineering (Bakhshinejad and Sadeghizadeh, 2014).
12. Corrosion control
For a long time, bacteria were known to cause corrosion due to the
chemical change they induce on metal surfaces. A biological method of
preventing corrosion is the use of lytic bacteriophages as bactericidal
agents (Zarasvand and Rai, 2014). The growth of microorganisms
within bioﬁlms contributes to serious issues in oilﬁeld systems, in-
cluding reservoir souring and corrosion (Baldwin and Summer, 2012).
Current methods of bioﬁlm control within the oil and gas industries
include physical removal and treatment with chemical biocides. Al-
though these methods can be eﬀective, incomplete bioﬁlm removal or
poor diﬀusion of chemicals into the bioﬁlm may allow for microbial
regrowth once treatment is halted (Baldwin and Summer, 2012).
Hence, a new and more eﬀective approach to controlling bioﬁlms could
make a signiﬁcant contribution to reducing the damage caused by mi-
crobially inﬂuenced corrosion. Bacteriophages have the ability to de-
grade the exopolysaccharide matrix that is a key constituent of bioﬁlms
and plays an important role in protecting the bacterial cells within a
bioﬁlm from chemical treatments (Baldwin and Summer, 2012). As
mentioned previously, the potential of bacteriophage particles for
tackling bacterial bioﬁlm growth on medical devices has been demon-
strated, as well as the success of bacteriophages in degrading bioﬁlm
polysaccharides and infecting cells. A similar performance in the oil and
gas industries would allow to use bacteriophages to be used as a more
eﬀective and targeted means of bioﬁlm treatment than currently de-
ployed methods. Petroleum reservoir souring, caused by microbially
induced production of hydrogen sulﬁde and other sulfur compounds,
and the associated corrosion, could be remediated by isolating speciﬁc
bacteriophage particles for the problematic (target) bacteria and adding
an eﬀective amount of such bacteriophage particles to the water in-
troduced into, or resident in, the reservoir, to kill at least some of the
target bacteria (Baldwin and Summer, 2012). The invention reported by
Baldwin and Summer (2012) relates to control of bacterial con-
tamination, corrosion, fouling and souring of oil and gas wells and re-
servoirs that result from injecting bacteria-contaminated water into a
well, especially bacteria producing acid and/or sulfur compounds that
cause reservoir souring, fouling and corrosion, using naturally occur-
ring bacteriophage particles, lytic for the targeted bacteria, particularly
sulfate-reducing bacteria and acid-producing bacteria. This biological
contamination process would allow the capital costs of creating new
wells to be decreased by maintaining sweet gas production, mitigating
the need for sour service pipes and hydrogen sulﬁde removal apparatus
(Baldwin and Summer, 2012). Similarly, bacterial contamination of
industrial water systems leads to biofouling by bioﬁlms and corrosion
from bacterially induced corrosion (Summer and Summer, 2012). The
invention reported by Summer and Summer (2012) relates to control of
bacterial contamination, corrosion and fouling, using naturally occur-
ring bacteriophage particles, lytic for the targeted bacteria. As the
elimination of corrosion-causing bacteria is necessary for corrosion
inhibition, the bacteriophage lytic cycle is a good alternative to using a
biocide. An advantage of bacteriophage particles over biocide use is its
self-replication ability, which increases the bacteriophage dosage over
the course of treatment (Zarasvand and Rai, 2014). Sulfate-reducing
bacteria are one of the causes of microbially induced corrosion and ﬁ-
lamentous bacteria such as Gordonia cause bulk foaming and process
upsets (Summer and Summer, 2012). The most widespread are mem-
bers of the delta subgroup of the Proteobacteria, including Desulfo-
bacterales, Desulfovibrionales, and Syntrophobacterales (Summer and
Summer, 2012). Bacteria selected for bacteriophage treatment may
include all members of the sulfate-reducing bacteria, including De-
sulfovibrio, Desulfotomaculum, Desulfobacter, and Desulfuromonas
(Summer and Summer, 2012). Speciﬁc members include Desulfovibrio
vulgaris and Desulfovibrio desulfuricans. These bacteria are also known to
mediate corrosion through interactions with the hydrogen ﬁlm on
water-exposed iron. Bacteria selected for bacteriophage treatment also
include those that produce acidic metabolites. This speciﬁcally includes
sulfur-oxidizing bacteria capable of generating sulfuric acid, viz. Thio-
bacilli thiooxidans and Thiobacilli denitriﬁcans (Summer and Summer,
2012).
13. Conclusions and future prospects
With the worldwide increase in research data pertaining to bacter-
iophage particles, the number of potential biotechnological applications
of these metabolically inert entities increases everyday. In fact,
humanity takes advantage of the natural predators of bacteria to ﬁght
pathogens and to increase the quality of life. Bacteriophages are the
most abundant biological entities in our biosphere, infecting speciﬁc
bacteria in every known environment, and their genetic diversity is
stunning. Due to their ability to transmit infection from one cell to
another, they play an important role in gene transfer among bacterial
populations and in maintaining ecological balance in microbial com-
munities. Studies of bacteriophages provide insights into genome evo-
lution, bacterial adaptation to new conditions, DNA expression and
replication, and they potentially provide new biotechnology products.
Compared to bacterial genomics, bacteriophage genomics has ad-
vanced slowly, and a higher-resolution picture of the phagosphere is
still only emerging. Phage genomes encode products that have been
useful for biotechnology applications including food biopreservation
and safety, diagnostics and therapeutics, bacterial biosensing, plant and
animal gene transfer methods, antimicrobial therapy, vaccine carriers,
antibiotic resistant strain therapeutics, DNA delivery vehicles, strain
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construction, gene delivery, biocontrol of plant pathogens, bacter-
iophage display, bioﬁlm control, nanotechnology, and corrosion con-
trol, just to mention a few. Nowadays, through genetic engineering and
recombinant DNA technology, it is possible to develop transgenic bac-
teriophage particles, lysins and other antibacterial phage proteins, in
order to increase their ability to infect bioﬁlms and make them more
speciﬁc and stable, with a wider spectrum of action and increasing both
their potency and eﬃcacy. Among phage-based technologies, we ﬁnd
two that seem to be the cutting edge in the ﬁeld. First, phage display
technology, that constantly delivers novel therapeutics and therapeutic
strategies for medicine. Second, phage-derived enzymes. These en-
zymes are not only simple proteins capable to lyse bacteria, but also a
source of bacteria-binding domains, bioﬁlm degrading products, and
other active elements that in the future can play a role of useful bio-
blocks for further engineering.
This review was written with the goal of showing the increasing
diversity of bacteriophage applications in modern society. However,
one must not forget that the initial interest in bacteriophage particles
arose primarily from the study in 1917, in Paris, by Felix d’Herelle who
applied them to treat infectious diseases in the era before the discovery
of antibiotics. The consistent discoveries of all new antibiotics and their
successful uses led to both a belief that they could be used indeﬁnitely
and to the oblivion of the idea of bacteriophage therapy. However, the
rapid emergence of problems with the search for, and introduction of,
new chemical antibiotic molecules, brought back the memory of phage
therapy. Hence, it is of utmost importance to develop a code of use of
bacteriophages in medical phage therapy, indirectly or directly re-
stricting some non-medical applications of bacteriophages. For ex-
ample, the use of bacteriophages to disinfect contaminated medical
devices and wash ﬂoors in hospitals should be avoided at all costs, as it
would inevitably lead to the emergence and spread of bacteriophage-
resistant pathogenic bacteria. It is also necessary to bear in mind the
potential for the emergence of new bacterial pathogens as a con-
sequence of the co-conductance of bacteriophages in bacteria, for ex-
ample, as a follow-up to the interspecies migration of the genomes of
moderate bacteriophages with a wide spectrum of lytic activity. This
will allow preservation of the possibility to use phage therapy in cases
of full bacterial resistance to available antibiotics. Due to the vast
number of existing bacteriophages, and the even larger number of un-
explored genes that they carry, further research is of utmost importance
to deepen the current knowledge about these metabolically inert pro-
tein entities and fully understand and beneﬁt from the biology and
biotechnology of bacteriophages.
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